{
  "doc_id": "24",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "中国2型糖尿病患者餐后高血糖管理专家共识",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "中国2型糖尿病患者餐后高血糖管理专家共识",
          "start_idx": 0,
          "end_idx": 20,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T1",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T2",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 14,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R0",
              "head_entity_id": "T1",
              "tail_entity_id": "T0"
            }
          ],
          "sentence_en": "Expert consensus on the management of postprandial hyperglycemia in patients with type 2 diabetes in China"
        }
      ],
      "paragraph_en": "Expert consensus on the management of postprandial hyperglycemia in patients with type 2 diabetes in China"
    },
    {
      "paragraph_id": "2",
      "paragraph": "一、餐后高血糖的定义和病理生理基础",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "一、餐后高血糖的定义和病理生理基础",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [
            {
              "entity_id": "T3",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "1. Definition and pathophysiological basis of postprandial hyperglycemia"
        }
      ],
      "paragraph_en": "1. Definition and pathophysiological basis of postprandial hyperglycemia"
    },
    {
      "paragraph_id": "4",
      "paragraph": "二、餐后高血糖的临床意义",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二、餐后高血糖的临床意义",
          "start_idx": 0,
          "end_idx": 12,
          "entities": [
            {
              "entity_id": "T4",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "2. Clinical significance of postprandial hyperglycemia"
        }
      ],
      "paragraph_en": "2. Clinical significance of postprandial hyperglycemia"
    },
    {
      "paragraph_id": "5",
      "paragraph": "流行病学研究显示，餐后或负荷后高血糖与多种疾病相关，但目前尚无十分充足的临床证据支持在糖尿病患者中特异性的干预餐后高血糖比干预整体血糖有更多的临床收益。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "流行病学研究显示，餐后或负荷后高血糖与多种疾病相关，但目前尚无十分充足的临床证据支持在糖尿病患者中特异性的干预餐后高血糖比干预整体血糖有更多的临床收益。",
          "start_idx": 0,
          "end_idx": 76,
          "entities": [
            {
              "entity_id": "T5",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 43,
              "end_idx": 46,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T6",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 65,
              "end_idx": 67,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T7",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T8",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 57,
              "end_idx": 60,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R1",
              "head_entity_id": "T6",
              "tail_entity_id": "T5"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R2",
              "head_entity_id": "T6",
              "tail_entity_id": "T8"
            }
          ],
          "sentence_en": "Epidemiological studies have shown that postprandial or post-load hyperglycemia is associated with a variety of diseases, but there is currently insufficient clinical evidence to support that specific intervention of postprandial hyperglycemia in diabetic patients has more clinical benefits than intervention of overall blood sugar."
        }
      ],
      "paragraph_en": "Epidemiological studies have shown that postprandial or post-load hyperglycemia is associated with a variety of diseases, but there is currently insufficient clinical evidence to support that specific intervention of postprandial hyperglycemia in diabetic patients has more clinical benefits than intervention of overall blood sugar."
    },
    {
      "paragraph_id": "6",
      "paragraph": "1.餐后高血糖与糖尿病微血管并发症发生的风险增高相关：餐后高血糖比HbA1c能更好地预测DR的发生发展。可能的机制是快速升高的PPG造成血糖波动，导致视网膜血管内皮功能下降、血管反应性增加。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.餐后高血糖与糖尿病微血管并发症发生的风险增高相关：餐后高血糖比HbA1c能更好地预测DR的发生发展。",
          "start_idx": 0,
          "end_idx": 52,
          "entities": [
            {
              "entity_id": "T9",
              "entity": "糖尿病微血管并发症",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 17,
              "entity_en": "Diabetic microvascular complications"
            },
            {
              "entity_id": "T10",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 33,
              "end_idx": 38,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T11",
              "entity": "DR",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 46,
              "entity_en": "DR"
            },
            {
              "entity_id": "T15",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T16",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 29,
              "end_idx": 32,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T17",
              "entity": "微血管",
              "entity_type": "Anatomy",
              "start_idx": 11,
              "end_idx": 14,
              "entity_en": "Microvascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R3",
              "head_entity_id": "T17",
              "tail_entity_id": "T9"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R4",
              "head_entity_id": "T10",
              "tail_entity_id": "T11"
            }
          ],
          "sentence_en": "1. Postprandial hyperglycemia is associated with an increased risk of diabetic microvascular complications: Postprandial hyperglycemia can better predict the occurrence and development of DR than HbA1c."
        },
        {
          "sentence_id": "1",
          "sentence": "可能的机制是快速升高的PPG造成血糖波动，导致视网膜血管内皮功能下降、血管反应性增加。",
          "start_idx": 52,
          "end_idx": 95,
          "entities": [
            {
              "entity_id": "T12",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 11,
              "end_idx": 14,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T13",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 16,
              "end_idx": 18,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T14",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 18,
              "end_idx": 20,
              "entity_en": "fluctuation"
            }
          ],
          "relations": [],
          "sentence_en": "The possible mechanism is that the rapid increase in PPG causes blood sugar fluctuations, leading to decreased retinal endothelial function and increased vascular reactivity."
        }
      ],
      "paragraph_en": "1. Postprandial hyperglycemia is associated with an increased risk of diabetic microvascular complications: Postprandial hyperglycemia can better predict the occurrence and development of DR than HbA1c. The possible mechanism is that the rapid increase in PPG causes blood sugar fluctuations, leading to decreased retinal endothelial function and increased vascular reactivity."
    },
    {
      "paragraph_id": "7",
      "paragraph": "2.餐后高血糖与糖尿病大血管并发症发生的风险增高相关：流行病学研究显示，餐后或糖负荷后血糖与心血管风险及其结局相关。PPG预测心血管事件的作用优于FPG。多项流行病学观察性研究发现，2 hPG是全因死亡和心血管死亡的独立危险因素，也是心血管疾病和全因死亡的预测因素。餐后高血糖与心血管疾病风险增加相关的机制可能与血糖波动有关。急性血糖升高会快速抑制内皮型一氧化氮(NO)释放及内皮依赖性血管扩张，增加可溶性黏附分子水平，并可能激活血栓形成。急性血糖波动比慢性持续性高血糖更显著地促进氧化应激(OS)反应和损害内皮功能。如果能降低餐后高血糖，则可改善0S、炎症和内皮细胞功能，有可能降低血栓形成的风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.餐后高血糖与糖尿病大血管并发症发生的风险增高相关：流行病学研究显示，餐后或糖负荷后血糖与心血管风险及其结局相关。PPG预测心血管事件的作用优于FPG。多项流行病学观察性研究发现，2 hPG是全因死亡和心血管死亡的独立危险因素，也是心血管疾病和全因死亡的预测因素。餐后高血糖与心血管疾病风险增加相关的机制可能与血糖波动有关。急性血糖升高会快速抑制内皮型一氧化氮(NO)释放及内皮依赖性血管扩张，增加可溶性黏附分子水平，并可能激活血栓形成。",
          "start_idx": 0,
          "end_idx": 220,
          "entities": [
            {
              "entity_id": "T18",
              "entity": "糖尿病大血管并发症",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 17,
              "entity_en": "Macrovascular complications of diabetes"
            },
            {
              "entity_id": "T19",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 63,
              "end_idx": 68,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T20",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 58,
              "end_idx": 61,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T21",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 73,
              "end_idx": 76,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T22",
              "entity": "2 hPG",
              "entity_type": "Test_items",
              "start_idx": 91,
              "end_idx": 96,
              "entity_en": "2 hPG"
            },
            {
              "entity_id": "T23",
              "entity": "心血管死亡",
              "entity_type": "Disease",
              "start_idx": 102,
              "end_idx": 107,
              "entity_en": "Cardiovascular death"
            },
            {
              "entity_id": "T24",
              "entity": "全因死亡",
              "entity_type": "Disease",
              "start_idx": 97,
              "end_idx": 101,
              "entity_en": "All-cause death"
            },
            {
              "entity_id": "T25",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 102,
              "end_idx": 105,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T26",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 63,
              "end_idx": 66,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T27",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 117,
              "end_idx": 122,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T28",
              "entity": "全因死亡",
              "entity_type": "Disease",
              "start_idx": 123,
              "end_idx": 127,
              "entity_en": "All-cause death"
            },
            {
              "entity_id": "T29",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 117,
              "end_idx": 120,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T30",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 139,
              "end_idx": 144,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T31",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 139,
              "end_idx": 142,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T32",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 156,
              "end_idx": 158,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T33",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 158,
              "end_idx": 160,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T34",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 165,
              "end_idx": 167,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T35",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 167,
              "end_idx": 169,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T36",
              "entity": "血栓",
              "entity_type": "Disease",
              "start_idx": 215,
              "end_idx": 217,
              "entity_en": "thrombus"
            },
            {
              "entity_id": "T41",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T42",
              "entity": "糖负荷后血糖",
              "entity_type": "Test_items",
              "start_idx": 39,
              "end_idx": 45,
              "entity_en": "Post-sugar load blood glucose"
            },
            {
              "entity_id": "T43",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 135,
              "end_idx": 138,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T45",
              "entity": "血管",
              "entity_type": "Anatomy",
              "start_idx": 12,
              "end_idx": 14,
              "entity_en": "Blood vessel"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R5",
              "head_entity_id": "T45",
              "tail_entity_id": "T18"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R6",
              "head_entity_id": "T20",
              "tail_entity_id": "T19"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R7",
              "head_entity_id": "T21",
              "tail_entity_id": "T19"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R8",
              "head_entity_id": "T26",
              "tail_entity_id": "T19"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R9",
              "head_entity_id": "T22",
              "tail_entity_id": "T23"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R10",
              "head_entity_id": "T22",
              "tail_entity_id": "T24"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R11",
              "head_entity_id": "T25",
              "tail_entity_id": "T23"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R12",
              "head_entity_id": "T29",
              "tail_entity_id": "T27"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R13",
              "head_entity_id": "T31",
              "tail_entity_id": "T30"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R14",
              "head_entity_id": "T32",
              "tail_entity_id": "T30"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R15",
              "head_entity_id": "T32",
              "tail_entity_id": "T43"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R16",
              "head_entity_id": "T34",
              "tail_entity_id": "T36"
            }
          ],
          "sentence_en": "2. Postprandial hyperglycemia is associated with an increased risk of macrovascular complications of diabetes: Epidemiological studies have shown that blood glucose after meals or after sugar load is associated with cardiovascular risk and its outcomes. PPG is better than FPG in predicting cardiovascular events. Several epidemiological observational studies have found that 2 hPG is an independent risk factor for all-cause mortality and cardiovascular mortality, and is also a predictor of cardiovascular disease and all-cause mortality. The mechanism by which postprandial hyperglycemia is associated with an increased risk of cardiovascular disease may be related to blood glucose fluctuations. Acute increases in blood glucose can rapidly inhibit endothelial nitric oxide (NO) release and endothelium-dependent vasodilation, increase the level of soluble adhesion molecules, and may activate thrombosis."
        },
        {
          "sentence_id": "1",
          "sentence": "急性血糖波动比慢性持续性高血糖更显著地促进氧化应激(OS)反应和损害内皮功能。",
          "start_idx": 220,
          "end_idx": 259,
          "entities": [
            {
              "entity_id": "T37",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T38",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T40",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 15,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "Acute hyperglycemia promotes oxidative stress (OS) and impairs endothelial function more significantly than chronic persistent hyperglycemia."
        },
        {
          "sentence_id": "2",
          "sentence": "如果能降低餐后高血糖，则可改善0S、炎症和内皮细胞功能，有可能降低血栓形成的风险。",
          "start_idx": 259,
          "end_idx": 300,
          "entities": [
            {
              "entity_id": "T39",
              "entity": "血栓",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 35,
              "entity_en": "thrombus"
            },
            {
              "entity_id": "T44",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "If postprandial hyperglycemia can be reduced, OS, inflammation and endothelial cell function can be improved, which may reduce the risk of thrombosis."
        }
      ],
      "paragraph_en": "2. Postprandial hyperglycemia is associated with an increased risk of diabetic macrovascular complications: Epidemiological studies have shown that postprandial or post-sugar load blood glucose is associated with cardiovascular risk and its outcomes. PPG is better than FPG in predicting cardiovascular events. Several epidemiological observational studies have found that 2 hPG is an independent risk factor for all-cause mortality and cardiovascular mortality, and is also a predictor of cardiovascular disease and all-cause mortality. The mechanism by which postprandial hyperglycemia is associated with an increased risk of cardiovascular disease may be related to blood glucose fluctuations. Acute increases in blood glucose rapidly inhibit endothelial nitric oxide (NO) release and endothelium-dependent vasodilation, increase the level of soluble adhesion molecules, and may activate thrombosis. Acute blood glucose fluctuations promote oxidative stress (OS) responses and damage endothelial function more significantly than chronic persistent hyperglycemia. If postprandial hyperglycemia can be reduced, OS, inflammation, and endothelial cell function can be improved, which may reduce the risk of thrombosis."
    },
    {
      "paragraph_id": "8",
      "paragraph": "3.餐后高血糖与多项心血管疾病的危险因素相关：餐后高血糖升高渗透压，可增加血小板反应性，激活血小板，与餐后高凝状态相关。餐后高血糖可减少心肌血容量及心肌血流。研究显示，糖尿病患者餐后心肌血容量及心肌血流较正常对照者下降。餐后高血糖及血糖波动与颈动脉内-中膜厚度(CIMT)增加相关。降低餐后高血糖、减少血糖波动有可能延缓或减轻CIMT进展。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.餐后高血糖与多项心血管疾病的危险因素相关：餐后高血糖升高渗透压，可增加血小板反应性，激活血小板，与餐后高凝状态相关。餐后高血糖可减少心肌血容量及心肌血流。研究显示，糖尿病患者餐后心肌血容量及心肌血流较正常对照者下降。餐后高血糖及血糖波动与颈动脉内-中膜厚度(CIMT)增加相关。降低餐后高血糖、减少血糖波动有可能延缓或减轻CIMT进展。",
          "start_idx": 0,
          "end_idx": 170,
          "entities": [
            {
              "entity_id": "T46",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T47",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 10,
              "end_idx": 13,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T48",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 116,
              "end_idx": 118,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T49",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 118,
              "end_idx": 120,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T50",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 151,
              "end_idx": 153,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T51",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 153,
              "end_idx": 155,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T52",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 84,
              "end_idx": 87,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T53",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T54",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 28,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T55",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 62,
              "end_idx": 65,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T56",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 112,
              "end_idx": 115,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T57",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 145,
              "end_idx": 148,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T58",
              "entity": "颈动脉内-中膜厚度(CIMT)增加",
              "entity_type": "Reason",
              "start_idx": 121,
              "end_idx": 138,
              "entity_en": "Increased carotid intima-media thickness (CIMT)"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R17",
              "head_entity_id": "T47",
              "tail_entity_id": "T46"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R18",
              "head_entity_id": "T48",
              "tail_entity_id": "T56"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R19",
              "head_entity_id": "T50",
              "tail_entity_id": "T57"
            },
            {
              "relation_type": "Reason_Disease",
              "relation_id": "R20",
              "head_entity_id": "T58",
              "tail_entity_id": "T56"
            }
          ],
          "sentence_en": "3. Postprandial hyperglycemia is associated with multiple risk factors for cardiovascular disease: Postprandial hyperglycemia increases osmotic pressure, increases platelet reactivity, activates platelets, and is associated with postprandial hypercoagulability. Postprandial hyperglycemia can reduce myocardial blood volume and blood flow. Studies have shown that myocardial blood volume and blood flow in diabetic patients after meals are lower than those in normal controls. Postprandial hyperglycemia and blood sugar fluctuations are associated with increased carotid intima-media thickness (CIMT). Reducing postprandial hyperglycemia and reducing blood sugar fluctuations may delay or alleviate the progression of CIMT."
        }
      ],
      "paragraph_en": "3. Postprandial hyperglycemia is associated with multiple risk factors for cardiovascular disease: Postprandial hyperglycemia increases osmotic pressure, increases platelet reactivity, activates platelets, and is associated with postprandial hypercoagulability. Postprandial hyperglycemia can reduce myocardial blood volume and blood flow. Studies have shown that myocardial blood volume and blood flow in diabetic patients after meals are lower than those in normal controls. Postprandial hyperglycemia and blood sugar fluctuations are associated with increased carotid intima-media thickness (CIMT). Reducing postprandial hyperglycemia and reducing blood sugar fluctuations may delay or alleviate the progression of CIMT."
    },
    {
      "paragraph_id": "9",
      "paragraph": "4.餐后高血糖对机体的其他不良影响：随着病程进展，胰岛β细胞功能减退及餐后血糖逐渐升高，而增高的餐后高血糖及血糖波动可使胰岛β细胞能进一步恶化。此外，有学者发现，餐后高血糖和PPG波动与老年人整体认知、执行和注意力障碍有关。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.餐后高血糖对机体的其他不良影响：随着病程进展，胰岛β细胞功能减退及餐后血糖逐渐升高，而增高的餐后高血糖及血糖波动可使胰岛β细胞能进一步恶化。此外，有学者发现，餐后高血糖和PPG波动与老年人整体认知、执行和注意力障碍有关。",
          "start_idx": 0,
          "end_idx": 112,
          "entities": [
            {
              "entity_id": "T59",
              "entity": "胰岛β细胞功能减退",
              "entity_type": "Pathogenesis",
              "start_idx": 25,
              "end_idx": 34,
              "entity_en": "Pancreatic β-cell dysfunction"
            },
            {
              "entity_id": "T60",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 35,
              "end_idx": 39,
              "entity_en": "Postprandial blood sugar"
            },
            {
              "entity_id": "T61",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 41,
              "end_idx": 43,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T62",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 54,
              "end_idx": 56,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T63",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 56,
              "end_idx": 58,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T64",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 87,
              "end_idx": 90,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T65",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 90,
              "end_idx": 92,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T66",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T67",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 50,
              "end_idx": 53,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T68",
              "entity": "胰岛β细胞能进一步恶化",
              "entity_type": "Pathogenesis",
              "start_idx": 60,
              "end_idx": 71,
              "entity_en": "Pancreatic beta cells can further deteriorate"
            },
            {
              "entity_id": "T69",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 83,
              "end_idx": 86,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T70",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 87,
              "end_idx": 90,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T71",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 90,
              "end_idx": 92,
              "entity_en": "fluctuation"
            }
          ],
          "relations": [
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R21",
              "head_entity_id": "T59",
              "tail_entity_id": "T66"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R22",
              "head_entity_id": "T60",
              "tail_entity_id": "T66"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R23",
              "head_entity_id": "T62",
              "tail_entity_id": "T67"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R24",
              "head_entity_id": "T68",
              "tail_entity_id": "T67"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R25",
              "head_entity_id": "T70",
              "tail_entity_id": "T69"
            }
          ],
          "sentence_en": "4. Other adverse effects of postprandial hyperglycemia on the body: As the disease progresses, pancreatic β-cell function declines and postprandial blood sugar gradually increases, and increased postprandial hyperglycemia and blood sugar fluctuations can further deteriorate pancreatic β-cell function. In addition, some scholars have found that postprandial hyperglycemia and PPG fluctuations are related to overall cognitive, executive and attention disorders in the elderly."
        }
      ],
      "paragraph_en": "4. Other adverse effects of postprandial hyperglycemia on the body: As the disease progresses, pancreatic β-cell function declines and postprandial blood sugar gradually increases, and increased postprandial hyperglycemia and blood sugar fluctuations can further deteriorate pancreatic β-cell function. In addition, some scholars have found that postprandial hyperglycemia and PPG fluctuations are related to overall cognitive, executive and attention disorders in the elderly."
    },
    {
      "paragraph_id": "10",
      "paragraph": "5.PPG与HbA1c的关系：HbA1c代表2~3个月的平均血糖水平，由FPG和PPG共同促进形成。横断面流行病学研究显示，HbA1c越接近正常值，PPG对其形成的贡献就越大，当HbA1c<7.3%时，PPG的贡献占70%；HbA1c7.3%~9.2%，PPG的贡献约50%；即使HbA1c>9.3%时，PPG的贡献仍占40%。但上述研究结果对临床治疗的指导价值尚需前瞻性临床研究验证。(表1)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.PPG与HbA1c的关系：HbA1c代表2~3个月的平均血糖水平，由FPG和PPG共同促进形成。",
          "start_idx": 0,
          "end_idx": 50,
          "entities": [
            {
              "entity_id": "T72",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T73",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 6,
              "end_idx": 11,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T74",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 15,
              "end_idx": 20,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T75",
              "entity": "血糖",
              "entity_type": "Test_Value",
              "start_idx": 30,
              "end_idx": 32,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T76",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 36,
              "end_idx": 39,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T77",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 40,
              "end_idx": 43,
              "entity_en": "PPG"
            }
          ],
          "relations": [],
          "sentence_en": "5. The relationship between PPG and HbA1c: HbA1c represents the average blood sugar level for 2 to 3 months and is jointly promoted by FPG and PPG."
        },
        {
          "sentence_id": "1",
          "sentence": "横断面流行病学研究显示，HbA1c越接近正常值，PPG对其形成的贡献就越大，当HbA1c<7.3%时，PPG的贡献占70%；HbA1c7.3%~9.2%，PPG的贡献约50%；即使HbA1c>9.3%时，PPG的贡献仍占40%。",
          "start_idx": 50,
          "end_idx": 164,
          "entities": [
            {
              "entity_id": "T78",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 12,
              "end_idx": 17,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T79",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 24,
              "end_idx": 27,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T80",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 39,
              "end_idx": 44,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T81",
              "entity": "<7.3%",
              "entity_type": "Test_Value",
              "start_idx": 44,
              "end_idx": 49,
              "entity_en": "<7.3%"
            },
            {
              "entity_id": "T82",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 51,
              "end_idx": 54,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T83",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 62,
              "end_idx": 67,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T84",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 77,
              "end_idx": 80,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T85",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 90,
              "end_idx": 95,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T86",
              "entity": ">9.3%",
              "entity_type": "Test_Value",
              "start_idx": 95,
              "end_idx": 100,
              "entity_en": ">9.3%"
            },
            {
              "entity_id": "T87",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 102,
              "end_idx": 105,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T88",
              "entity": "7.3%~9.2%",
              "entity_type": "Test_Value",
              "start_idx": 67,
              "end_idx": 76,
              "entity_en": "7.3%~9.2%"
            },
            {
              "entity_id": "T89",
              "entity": "接近正常值",
              "entity_type": "Test_Value",
              "start_idx": 18,
              "end_idx": 23,
              "entity_en": "Close to normal"
            }
          ],
          "relations": [],
          "sentence_en": "Cross-sectional epidemiological studies have shown that the closer HbA1c is to normal values, the greater the contribution of PPG to its formation. When HbA1c is <7.3%, PPG's contribution is 70%; when HbA1c is 7.3%~9.2%, PPG's contribution is about 50%; even when HbA1c is >9.3%, PPG's contribution is still 40%."
        },
        {
          "sentence_id": "2",
          "sentence": "但上述研究结果对临床治疗的指导价值尚需前瞻性临床研究验证。",
          "start_idx": 164,
          "end_idx": 193,
          "entities": [],
          "relations": [],
          "sentence_en": "However, the guiding value of the above research results for clinical treatment still needs to be verified by prospective clinical studies."
        },
        {
          "sentence_id": "3",
          "sentence": "(表1)",
          "start_idx": 193,
          "end_idx": 197,
          "entities": [],
          "relations": [],
          "sentence_en": "(Table 1)"
        }
      ],
      "paragraph_en": "5. Relationship between PPG and HbA1c: HbA1c represents the average blood sugar level for 2 to 3 months, which is jointly promoted by FPG and PPG. Cross-sectional epidemiological studies have shown that the closer HbA1c is to the normal value, the greater the contribution of PPG to its formation. When HbA1c <7.3%, PPG contributes 70%; when HbA1c is 7.3% to 9.2%, PPG contributes about 50%; even when HbA1c>9.3%, PPG still contributes 40%. However, the guiding value of the above research results for clinical treatment still needs to be verified by prospective clinical studies. (Table 1)"
    },
    {
      "paragraph_id": "11",
      "paragraph": "三、餐后高血糖的检测",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "三、餐后高血糖的检测",
          "start_idx": 0,
          "end_idx": 10,
          "entities": [
            {
              "entity_id": "T90",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "3. Detection of postprandial hyperglycemia"
        }
      ],
      "paragraph_en": "3. Detection of postprandial hyperglycemia"
    },
    {
      "paragraph_id": "12",
      "paragraph": "1.检测对象：对于以下临床状态的患者，可通过监测PPG评价疗效、低血糖风险和指导药物剂量调整。(1)任何HbA1c不达标的T2DM患者，尤其是FPG达标，而HbA1c不达标，如FPG<6.0mmol/L，但HbA1c>7.0%；(2)低血糖风险较高的患者，如使用促泌剂或胰岛素治疗、进餐不规律或餐后剧烈运动者；(3)使用降糖药物，尤其是降低PPG的药物时。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.检测对象：对于以下临床状态的患者，可通过监测PPG评价疗效、低血糖风险和指导药物剂量调整。(1)任何HbA1c不达标的T2DM患者，尤其是FPG达标，而HbA1c不达标，如FPG<6.0mmol/L，但HbA1c>7.0%；(2)低血糖风险较高的患者，如使用促泌剂或胰岛素治疗、进餐不规律或餐后剧烈运动者；(3)使用降糖药物，尤其是降低PPG的药物时。",
          "start_idx": 0,
          "end_idx": 178,
          "entities": [
            {
              "entity_id": "T91",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 35,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T92",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 52,
              "end_idx": 57,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T93",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 61,
              "end_idx": 65,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T94",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 61,
              "end_idx": 63,
              "entity_en": "T2"
            },
            {
              "entity_id": "T95",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 71,
              "end_idx": 74,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T96",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 78,
              "end_idx": 83,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T97",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 88,
              "end_idx": 91,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T98",
              "entity": "<6.0mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 91,
              "end_idx": 101,
              "entity_en": "<6.0mmol/L"
            },
            {
              "entity_id": "T99",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 103,
              "end_idx": 108,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T100",
              "entity": ">7.0%",
              "entity_type": "Test_Value",
              "start_idx": 108,
              "end_idx": 113,
              "entity_en": ">7.0%"
            },
            {
              "entity_id": "T101",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 117,
              "end_idx": 120,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T102",
              "entity": "促泌剂",
              "entity_type": "Drug",
              "start_idx": 131,
              "end_idx": 134,
              "entity_en": "Secretagogues"
            },
            {
              "entity_id": "T103",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 135,
              "end_idx": 138,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T104",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 170,
              "end_idx": 173,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T105",
              "entity": "监测PPG",
              "entity_type": "Test_items",
              "start_idx": 22,
              "end_idx": 27,
              "entity_en": "Monitoring PPG"
            },
            {
              "entity_id": "T106",
              "entity": "不达标",
              "entity_type": "Test_Value",
              "start_idx": 83,
              "end_idx": 86,
              "entity_en": "Not up to standard"
            },
            {
              "entity_id": "T107",
              "entity": "达标",
              "entity_type": "Test_Value",
              "start_idx": 74,
              "end_idx": 76,
              "entity_en": "Meet the Standard"
            },
            {
              "entity_id": "T108",
              "entity": "不达标",
              "entity_type": "Test_Value",
              "start_idx": 57,
              "end_idx": 60,
              "entity_en": "Not up to standard"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R26",
              "head_entity_id": "T105",
              "tail_entity_id": "T91"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R27",
              "head_entity_id": "T94",
              "tail_entity_id": "T93"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R28",
              "head_entity_id": "T95",
              "tail_entity_id": "T93"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R29",
              "head_entity_id": "T96",
              "tail_entity_id": "T93"
            }
          ],
          "sentence_en": "1. Target group: PPG monitoring can be used to evaluate the efficacy, risk of hypoglycemia, and guide drug dosage adjustment in patients with the following clinical conditions. (1) Any T2DM patient whose HbA1c is not up to standard, especially those whose FPG is up to standard but whose HbA1c is not, such as FPG < 6.0 mmol/L but HbA1c > 7.0%; (2) Patients at higher risk of hypoglycemia, such as those who use secretagogues or insulin therapy, have irregular meals, or do strenuous exercise after meals; (3) Patients who use glucose-lowering drugs, especially those that lower PPG."
        }
      ],
      "paragraph_en": "1. Target group: PPG monitoring can be used to evaluate the efficacy, risk of hypoglycemia, and guide drug dosage adjustment in patients with the following clinical conditions. (1) Any T2DM patient whose HbA1c is not up to standard, especially those whose FPG is up to standard but whose HbA1c is not, such as FPG < 6.0 mmol/L but HbA1c > 7.0%; (2) Patients at higher risk of hypoglycemia, such as those who use secretagogues or insulin therapy, have irregular meals, or do strenuous exercise after meals; (3) Patients who use glucose-lowering drugs, especially those that lower PPG."
    },
    {
      "paragraph_id": "13",
      "paragraph": "2.检测方法：需要监测PPG的糖尿病患者除3~6个月检测1次HbA1c外，还应通过自我血糖监测(SMBG)监测PPG。对于采用胰岛素强化治疗、血糖波动较大及低血糖风险较高者，可通过动态血糖监测(CGM)更好地指导治疗方案的调整。1，5-脱水葡萄糖醇(1，5-AG)也是反映短期餐后高血及血糖波动的指标，但其与并发症的关系有待进一步探讨。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.检测方法：需要监测PPG的糖尿病患者除3~6个月检测1次HbA1c外，还应通过自我血糖监测(SMBG)监测PPG。",
          "start_idx": 0,
          "end_idx": 59,
          "entities": [
            {
              "entity_id": "T109",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 18,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T110",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 35,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T111",
              "entity": "自我血糖监测(SMBG)",
              "entity_type": "Test_items",
              "start_idx": 41,
              "end_idx": 53,
              "entity_en": "Self-monitoring of blood glucose (SMBG)"
            },
            {
              "entity_id": "T112",
              "entity": "监测PPG",
              "entity_type": "Test_items",
              "start_idx": 53,
              "end_idx": 58,
              "entity_en": "Monitoring PPG"
            },
            {
              "entity_id": "T121",
              "entity": "监测PPG",
              "entity_type": "Test_items",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "Monitoring PPG"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R30",
              "head_entity_id": "T121",
              "tail_entity_id": "T109"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R31",
              "head_entity_id": "T110",
              "tail_entity_id": "T109"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R32",
              "head_entity_id": "T111",
              "tail_entity_id": "T109"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R33",
              "head_entity_id": "T112",
              "tail_entity_id": "T109"
            }
          ],
          "sentence_en": "2. Detection method: Diabetic patients who need to monitor PPG should monitor PPG through self-blood glucose monitoring (SMBG) in addition to testing HbA1c once every 3 to 6 months."
        },
        {
          "sentence_id": "1",
          "sentence": "对于采用胰岛素强化治疗、血糖波动较大及低血糖风险较高者，可通过动态血糖监测(CGM)更好地指导治疗方案的调整。",
          "start_idx": 59,
          "end_idx": 114,
          "entities": [
            {
              "entity_id": "T113",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T114",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 12,
              "end_idx": 14,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T115",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 14,
              "end_idx": 16,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T116",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 19,
              "end_idx": 22,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T117",
              "entity": "动态血糖监测(CGM)",
              "entity_type": "Test_items",
              "start_idx": 31,
              "end_idx": 42,
              "entity_en": "Continuous Glucose Monitoring (CGM)"
            }
          ],
          "relations": [],
          "sentence_en": "For those who receive intensive insulin therapy, have large blood sugar fluctuations, and are at higher risk of hypoglycemia, continuous glucose monitoring (CGM) can better guide adjustments to treatment plans."
        },
        {
          "sentence_id": "2",
          "sentence": "1，5-脱水葡萄糖醇(1，5-AG)也是反映短期餐后高血及血糖波动的指标，但其与并发症的关系有待进一步探讨。",
          "start_idx": 114,
          "end_idx": 168,
          "entities": [
            {
              "entity_id": "T118",
              "entity": "1，5-脱水葡萄糖醇(1，5-AG)",
              "entity_type": "Test_items",
              "start_idx": 0,
              "end_idx": 18,
              "entity_en": "1,5-Anhydroglucitol (1,5-AG)"
            },
            {
              "entity_id": "T119",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 29,
              "end_idx": 31,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T120",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 31,
              "end_idx": 33,
              "entity_en": "fluctuation"
            }
          ],
          "relations": [],
          "sentence_en": "1,5-anhydroglucitol (1,5-AG) is also an indicator of short-term postprandial hyperglycemia and blood sugar fluctuations, but its relationship with complications needs further exploration."
        }
      ],
      "paragraph_en": "2. Detection method: In addition to testing HbA1c once every 3 to 6 months, diabetic patients who need to monitor PPG should also monitor PPG through self-monitoring of blood glucose (SMBG). For those who use intensive insulin therapy, have large blood sugar fluctuations, and have a higher risk of hypoglycemia, continuous blood glucose monitoring (CGM) can better guide the adjustment of treatment plans. 1,5-anhydroglucitol (1,5-AG) is also an indicator of short-term postprandial hyperglycemia and blood sugar fluctuations, but its relationship with complications needs further discussion."
    },
    {
      "paragraph_id": "14",
      "paragraph": "3.PPG与血糖波动：血糖波动包括日间血糖波动和日内血糖波动，需要连续监测血糖来计算波动的大小。PPG升高和低血糖构成日内血糖波动，但餐后高血糖是日内血糖波动的主要原因。进餐引起的血糖波动与饮食习惯密切相关，如饮食量、食物种类[不同升糖指数(GI)的食物]及进食次数等。T2DM患者日内血糖波动高于非糖尿病人群，主原因在于餐后高血糖。(表2)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.PPG与血糖波动：血糖波动包括日间血糖波动和日内血糖波动，需要连续监测血糖来计算波动的大小。PPG升高和低血糖构成日内血糖波动，但餐后高血糖是日内血糖波动的主要原因。进餐引起的血糖波动与饮食习惯密切相关，如饮食量、食物种类[不同升糖指数(GI)的食物]及进食次数等。T2DM患者日内血糖波动高于非糖尿病人群，主原因在于餐后高血糖。",
          "start_idx": 0,
          "end_idx": 167,
          "entities": [
            {
              "entity_id": "T122",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T123",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 6,
              "end_idx": 8,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T124",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 8,
              "end_idx": 10,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T125",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 11,
              "end_idx": 13,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T126",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 13,
              "end_idx": 15,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T127",
              "entity": "日间血糖",
              "entity_type": "Test_items",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "Daytime blood sugar"
            },
            {
              "entity_id": "T128",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 21,
              "end_idx": 23,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T129",
              "entity": "日内血糖",
              "entity_type": "Test_items",
              "start_idx": 24,
              "end_idx": 28,
              "entity_en": "Daily blood sugar"
            },
            {
              "entity_id": "T130",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 28,
              "end_idx": 30,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T131",
              "entity": "监测血糖",
              "entity_type": "Test_items",
              "start_idx": 35,
              "end_idx": 39,
              "entity_en": "Monitoring blood sugar"
            },
            {
              "entity_id": "T132",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 42,
              "end_idx": 44,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T133",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 48,
              "end_idx": 51,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T134",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 51,
              "end_idx": 53,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T135",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 54,
              "end_idx": 57,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T136",
              "entity": "日内血糖",
              "entity_type": "Test_items",
              "start_idx": 59,
              "end_idx": 63,
              "entity_en": "Daily blood sugar"
            },
            {
              "entity_id": "T137",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 63,
              "end_idx": 65,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T138",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 69,
              "end_idx": 72,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T139",
              "entity": "日内血糖",
              "entity_type": "Test_items",
              "start_idx": 73,
              "end_idx": 77,
              "entity_en": "Daily blood sugar"
            },
            {
              "entity_id": "T140",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 77,
              "end_idx": 79,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T141",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 90,
              "end_idx": 92,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T142",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 92,
              "end_idx": 94,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T143",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 135,
              "end_idx": 139,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T144",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 135,
              "end_idx": 137,
              "entity_en": "T2"
            },
            {
              "entity_id": "T145",
              "entity": "日内血糖",
              "entity_type": "Test_items",
              "start_idx": 141,
              "end_idx": 145,
              "entity_en": "Daily blood sugar"
            },
            {
              "entity_id": "T146",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 145,
              "end_idx": 147,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T147",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 150,
              "end_idx": 153,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T148",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 163,
              "end_idx": 166,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R34",
              "head_entity_id": "T133",
              "tail_entity_id": "T135"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R35",
              "head_entity_id": "T136",
              "tail_entity_id": "T135"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R36",
              "head_entity_id": "T139",
              "tail_entity_id": "T138"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R37",
              "head_entity_id": "T144",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R38",
              "head_entity_id": "T145",
              "tail_entity_id": "T143"
            }
          ],
          "sentence_en": "3.PPG and blood sugar fluctuations: Blood sugar fluctuations include daytime blood sugar fluctuations and intraday blood sugar fluctuations. Continuous blood sugar monitoring is required to calculate the magnitude of the fluctuations. Increased PPG and hypoglycemia constitute intraday blood sugar fluctuations, but postprandial hyperglycemia is the main cause of intraday blood sugar fluctuations. Blood sugar fluctuations caused by meals are closely related to eating habits, such as food intake, food types [foods with different glycemic indexes (GI)], and number of meals. The intraday blood sugar fluctuations of T2DM patients are higher than those of non-diabetic people, mainly due to postprandial hyperglycemia."
        },
        {
          "sentence_id": "1",
          "sentence": "(表2)",
          "start_idx": 167,
          "end_idx": 171,
          "entities": [],
          "relations": [],
          "sentence_en": "(Table 2)"
        }
      ],
      "paragraph_en": "3.PPG and blood sugar fluctuations: Blood sugar fluctuations include daytime blood sugar fluctuations and intraday blood sugar fluctuations. Continuous blood sugar monitoring is required to calculate the magnitude of the fluctuations. Increased PPG and hypoglycemia constitute intraday blood sugar fluctuations, but postprandial hyperglycemia is the main cause of intraday blood sugar fluctuations. Blood sugar fluctuations caused by meals are closely related to eating habits, such as food intake, food types [foods with different glycemic indexes (GI)], and number of meals. The intraday blood sugar fluctuations of T2DM patients are higher than those of non-diabetic people, mainly due to postprandial hyperglycemia. (Table 2)"
    },
    {
      "paragraph_id": "15",
      "paragraph": "四、控制餐后高血糖的临床获益",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "四、控制餐后高血糖的临床获益",
          "start_idx": 0,
          "end_idx": 14,
          "entities": [
            {
              "entity_id": "T149",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "4. Clinical benefits of controlling postprandial hyperglycemia"
        }
      ],
      "paragraph_en": "4. Clinical benefits of controlling postprandial hyperglycemia"
    },
    {
      "paragraph_id": "16",
      "paragraph": "1.控制PPG助于HbA1c达标：单纯控制PPG可改善HbA1c。当HbA1c接近7%，而FPG控制达标时，加强PPG的控制可进一步增加其的贡献。临床试验显示，控制FPG达标(<5.6mmol/L的患者可有64%实现HbA1c<7%，而进一步控PPG达标(<7.8mmol/L)的患者则有94%实HbA1c<7%。由此可见，控制PPG有助于进一步提高整体血糖达标率。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.控制PPG助于HbA1c达标：单纯控制PPG可改善HbA1c。",
          "start_idx": 0,
          "end_idx": 33,
          "entities": [
            {
              "entity_id": "T150",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T151",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 9,
              "end_idx": 14,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T152",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 21,
              "end_idx": 24,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T153",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 27,
              "end_idx": 32,
              "entity_en": "HbA1c"
            }
          ],
          "relations": [],
          "sentence_en": "1. Controlling PPG helps achieve HbA1c target: Simply controlling PPG can improve HbA1c."
        },
        {
          "sentence_id": "1",
          "sentence": "当HbA1c接近7%，而FPG控制达标时，加强PPG的控制可进一步增加其的贡献。",
          "start_idx": 33,
          "end_idx": 73,
          "entities": [
            {
              "entity_id": "T154",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 1,
              "end_idx": 6,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T155",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 12,
              "end_idx": 15,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T156",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 23,
              "end_idx": 26,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T169",
              "entity": "达标",
              "entity_type": "Test_Value",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "Meet the Standard"
            },
            {
              "entity_id": "T170",
              "entity": "接近7%",
              "entity_type": "Test_Value",
              "start_idx": 6,
              "end_idx": 10,
              "entity_en": "Close to 7%"
            }
          ],
          "relations": [],
          "sentence_en": "When HbA1c is close to 7% and FPG control reaches the target, strengthening PPG control can further increase its contribution."
        },
        {
          "sentence_id": "2",
          "sentence": "临床试验显示，控制FPG达标(<5.6mmol/L的患者可有64%实现HbA1c<7%，而进一步控PPG达标(<7.8mmol/L)的患者则有94%实HbA1c<7%。",
          "start_idx": 73,
          "end_idx": 157,
          "entities": [
            {
              "entity_id": "T157",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 9,
              "end_idx": 12,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T158",
              "entity": "<5.6mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 15,
              "end_idx": 25,
              "entity_en": "<5.6mmol/L"
            },
            {
              "entity_id": "T159",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 35,
              "end_idx": 40,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T160",
              "entity": "<7%",
              "entity_type": "Test_Value",
              "start_idx": 40,
              "end_idx": 43,
              "entity_en": "<7%"
            },
            {
              "entity_id": "T161",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 49,
              "end_idx": 52,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T162",
              "entity": "<7.8mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 55,
              "end_idx": 65,
              "entity_en": "<7.8mmol/L"
            },
            {
              "entity_id": "T163",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 75,
              "end_idx": 80,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T164",
              "entity": "<7%",
              "entity_type": "Test_Value",
              "start_idx": 80,
              "end_idx": 83,
              "entity_en": "<7%"
            },
            {
              "entity_id": "T167",
              "entity": "达标",
              "entity_type": "Test_Value",
              "start_idx": 12,
              "end_idx": 14,
              "entity_en": "Meet the Standard"
            },
            {
              "entity_id": "T168",
              "entity": "达标",
              "entity_type": "Test_Value",
              "start_idx": 52,
              "end_idx": 54,
              "entity_en": "Meet the Standard"
            }
          ],
          "relations": [],
          "sentence_en": "Clinical trials have shown that 64% of patients who control FPG to the target (<5.6mmol/L) can achieve HbA1c <7%, while 94% of patients who further control PPG to the target (<7.8mmol/L) can achieve HbA1c <7%."
        },
        {
          "sentence_id": "3",
          "sentence": "由此可见，控制PPG有助于进一步提高整体血糖达标率。",
          "start_idx": 157,
          "end_idx": 183,
          "entities": [
            {
              "entity_id": "T165",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 7,
              "end_idx": 10,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T166",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 20,
              "end_idx": 22,
              "entity_en": "blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "This shows that controlling PPG helps to further improve the overall blood sugar target rate."
        }
      ],
      "paragraph_en": "1. Controlling PPG helps reach HbA1c target: Simply controlling PPG can improve HbA1c. When HbA1c is close to 7% and FPG is controlled to reach the target, strengthening PPG control can further increase its contribution. Clinical trials have shown that 64% of patients who control FPG to reach the target (<5.6mmol/L) can achieve HbA1c <7%, while 94% of patients who further control PPG to reach the target (<7.8mmol/L) can achieve HbA1c <7%. This shows that controlling PPG can help further improve the overall blood sugar target rate."
    },
    {
      "paragraph_id": "17",
      "paragraph": "2.控制餐后高血糖与心血管获益：针对性的控制餐后高血糖是否会使T2DM患者心血管疾病发生的风险下降尚无临床证据。HEART2D研究比较了胰岛素治疗控制空腹高血糖或餐后高血糖对急性心肌梗死后心血管终点的影响，结果显示，两组HbA1c水平比较，差异无统计学意义；FPG和PPG比较差异有统计学意义，但与降低FPG为主比较，降低餐后高血糖未能进一步降低复合心血管终点事件的风险。对该研究的亚组分析发现，在老年糖尿病患者中，控制餐后高血糖可降低心血管风险。对短期评价血糖控制的临床试验的荟萃分析(MeR-IA-7)结果显示，与安慰剂比较，降低PPG的药物，如阿卡波糖的治疗与心血管事件风险下降相关(心肌梗死的风险降低64%、任何心血管事件的风险降低35%)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.控制餐后高血糖与心血管获益：针对性的控制餐后高血糖是否会使T2DM患者心血管疾病发生的风险下降尚无临床证据。HEART2D研究比较了胰岛素治疗控制空腹高血糖或餐后高血糖对急性心肌梗死后心血管终点的影响，结果显示，两组HbA1c水平比较，差异无统计学意义；FPG和PPG比较差异有统计学意义，但与降低FPG为主比较，降低餐后高血糖未能进一步降低复合心血管终点事件的风险。对该研究的亚组分析发现，在老年糖尿病患者中，控制餐后高血糖可降低心血管风险。对短期评价血糖控制的临床试验的荟萃分析(MeR-IA-7)结果显示，与安慰剂比较，降低PPG的药物，如阿卡波糖的治疗与心血管事件风险下降相关(心肌梗死的风险降低64%、任何心血管事件的风险降低35%)。",
          "start_idx": 0,
          "end_idx": 325,
          "entities": [
            {
              "entity_id": "T171",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 6,
              "end_idx": 9,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T172",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 27,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T173",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 35,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T174",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 31,
              "end_idx": 33,
              "entity_en": "T2"
            },
            {
              "entity_id": "T175",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 42,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T176",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 37,
              "end_idx": 40,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T177",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 68,
              "end_idx": 71,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T178",
              "entity": "空腹高血糖",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 80,
              "entity_en": "Fasting high blood sugar"
            },
            {
              "entity_id": "T179",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 83,
              "end_idx": 86,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T180",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 89,
              "end_idx": 93,
              "entity_en": "Myocardial infarction"
            },
            {
              "entity_id": "T181",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 89,
              "end_idx": 91,
              "entity_en": "Myocardium"
            },
            {
              "entity_id": "T182",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 110,
              "end_idx": 115,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T183",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 129,
              "end_idx": 132,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T184",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 133,
              "end_idx": 136,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T185",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 151,
              "end_idx": 154,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T186",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 163,
              "end_idx": 166,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T187",
              "entity": "复合心血管终点事件",
              "entity_type": "Disease",
              "start_idx": 173,
              "end_idx": 182,
              "entity_en": "Composite cardiovascular endpoint"
            },
            {
              "entity_id": "T188",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 175,
              "end_idx": 178,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T189",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 201,
              "end_idx": 204,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T190",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 212,
              "end_idx": 215,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T191",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 229,
              "end_idx": 231,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T192",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 267,
              "end_idx": 270,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T193",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 275,
              "end_idx": 279,
              "entity_en": "Acarbose"
            },
            {
              "entity_id": "T194",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 283,
              "end_idx": 288,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T195",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 283,
              "end_idx": 286,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T196",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 295,
              "end_idx": 299,
              "entity_en": "Myocardial infarction"
            },
            {
              "entity_id": "T197",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 295,
              "end_idx": 297,
              "entity_en": "Myocardium"
            },
            {
              "entity_id": "T198",
              "entity": "心血管事件",
              "entity_type": "Disease",
              "start_idx": 310,
              "end_idx": 315,
              "entity_en": "Cardiovascular events"
            },
            {
              "entity_id": "T199",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 310,
              "end_idx": 313,
              "entity_en": "Cardiovascular"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R39",
              "head_entity_id": "T174",
              "tail_entity_id": "T173"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R40",
              "head_entity_id": "T176",
              "tail_entity_id": "T175"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R41",
              "head_entity_id": "T177",
              "tail_entity_id": "T179"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R42",
              "head_entity_id": "T177",
              "tail_entity_id": "T178"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R43",
              "head_entity_id": "T181",
              "tail_entity_id": "T180"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R44",
              "head_entity_id": "T182",
              "tail_entity_id": "T186"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R45",
              "head_entity_id": "T183",
              "tail_entity_id": "T186"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R46",
              "head_entity_id": "T184",
              "tail_entity_id": "T186"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R47",
              "head_entity_id": "T188",
              "tail_entity_id": "T187"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R48",
              "head_entity_id": "T192",
              "tail_entity_id": "T194"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R49",
              "head_entity_id": "T193",
              "tail_entity_id": "T194"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R50",
              "head_entity_id": "T195",
              "tail_entity_id": "T194"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R51",
              "head_entity_id": "T197",
              "tail_entity_id": "T196"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R52",
              "head_entity_id": "T199",
              "tail_entity_id": "T198"
            }
          ],
          "sentence_en": "2. Control of postprandial hyperglycemia and cardiovascular benefits: There is no clinical evidence whether targeted control of postprandial hyperglycemia can reduce the risk of cardiovascular disease in patients with T2DM. The HEART2D study compared the effects of insulin therapy to control fasting hyperglycemia or postprandial hyperglycemia on cardiovascular endpoints after acute myocardial infarction. The results showed that there was no statistically significant difference in HbA1c levels between the two groups; there was a statistically significant difference between FPG and PPG, but compared with the reduction of FPG as the main treatment, the reduction of postprandial hyperglycemia failed to further reduce the risk of composite cardiovascular endpoint events. Subgroup analysis of the study found that in elderly patients with diabetes, controlling postprandial hyperglycemia can reduce cardiovascular risk. The results of a meta-analysis of clinical trials evaluating short-term blood sugar control (MeR-IA-7) showed that compared with placebo, drugs that reduce PPG, such as acarbose, were associated with a reduced risk of cardiovascular events (a 64% reduction in the risk of myocardial infarction and a 35% reduction in the risk of any cardiovascular event)."
        }
      ],
      "paragraph_en": "2. Control of postprandial hyperglycemia and cardiovascular benefits: There is no clinical evidence whether targeted control of postprandial hyperglycemia can reduce the risk of cardiovascular disease in patients with T2DM. The HEART2D study compared the effects of insulin therapy to control fasting hyperglycemia or postprandial hyperglycemia on cardiovascular endpoints after acute myocardial infarction. The results showed that there was no statistically significant difference in HbA1c levels between the two groups; there was a statistically significant difference between FPG and PPG, but compared with the reduction of FPG as the main treatment, the reduction of postprandial hyperglycemia failed to further reduce the risk of composite cardiovascular endpoint events. Subgroup analysis of the study found that in elderly patients with diabetes, controlling postprandial hyperglycemia can reduce cardiovascular risk. The results of a meta-analysis of clinical trials evaluating short-term blood sugar control (MeR-IA-7) showed that compared with placebo, drugs that reduce PPG, such as acarbose, were associated with a reduced risk of cardiovascular events (a 64% reduction in the risk of myocardial infarction and a 35% reduction in the risk of any cardiovascular event)."
    },
    {
      "paragraph_id": "18",
      "paragraph": "3.降低PPG与改善心血管疾病危险因素相关：控制PPG与改善多种心血管疾病危险因素有关，如TC、TG、LDL-C降低和HDL-C升高；血压、高凝状态及炎症因子均降低；CIMT进展减慢等。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.降低PPG与改善心血管疾病危险因素相关：控制PPG与改善多种心血管疾病危险因素有关，如TC、TG、LDL-C降低和HDL-C升高；血压、高凝状态及炎症因子均降低；CIMT进展减慢等。",
          "start_idx": 0,
          "end_idx": 93,
          "entities": [
            {
              "entity_id": "T200",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T201",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 10,
              "end_idx": 15,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T202",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 10,
              "end_idx": 13,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T203",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 24,
              "end_idx": 27,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T204",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 37,
              "entity_en": "Cardiovascular disease"
            },
            {
              "entity_id": "T205",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 32,
              "end_idx": 35,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T206",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 67,
              "end_idx": 69,
              "entity_en": "blood pressure"
            },
            {
              "entity_id": "T207",
              "entity": "炎症因子",
              "entity_type": "Test_items",
              "start_idx": 75,
              "end_idx": 79,
              "entity_en": "Inflammatory factors"
            },
            {
              "entity_id": "T208",
              "entity": "高凝状态",
              "entity_type": "Test_items",
              "start_idx": 70,
              "end_idx": 74,
              "entity_en": "Hypercoagulable state"
            },
            {
              "entity_id": "T209",
              "entity": "降低",
              "entity_type": "Test_Value",
              "start_idx": 80,
              "end_idx": 82,
              "entity_en": "reduce"
            },
            {
              "entity_id": "T210",
              "entity": "HDL-C",
              "entity_type": "Test_items",
              "start_idx": 59,
              "end_idx": 64,
              "entity_en": "HDL-C"
            },
            {
              "entity_id": "T211",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 64,
              "end_idx": 66,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T212",
              "entity": "TC",
              "entity_type": "Test_items",
              "start_idx": 45,
              "end_idx": 47,
              "entity_en": "TC"
            },
            {
              "entity_id": "T213",
              "entity": "TG",
              "entity_type": "Test_items",
              "start_idx": 48,
              "end_idx": 50,
              "entity_en": "TG"
            },
            {
              "entity_id": "T214",
              "entity": "LDL-C",
              "entity_type": "Test_items",
              "start_idx": 51,
              "end_idx": 56,
              "entity_en": "LDL-C"
            },
            {
              "entity_id": "T215",
              "entity": "降低",
              "entity_type": "Test_Value",
              "start_idx": 56,
              "end_idx": 58,
              "entity_en": "reduce"
            },
            {
              "entity_id": "T216",
              "entity": "HDL-C",
              "entity_type": "Test_items",
              "start_idx": 59,
              "end_idx": 64,
              "entity_en": "HDL-C"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R53",
              "head_entity_id": "T200",
              "tail_entity_id": "T201"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R54",
              "head_entity_id": "T202",
              "tail_entity_id": "T201"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R55",
              "head_entity_id": "T203",
              "tail_entity_id": "T204"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R56",
              "head_entity_id": "T205",
              "tail_entity_id": "T204"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R57",
              "head_entity_id": "T212",
              "tail_entity_id": "T204"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R58",
              "head_entity_id": "T213",
              "tail_entity_id": "T204"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R59",
              "head_entity_id": "T214",
              "tail_entity_id": "T204"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R60",
              "head_entity_id": "T216",
              "tail_entity_id": "T204"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R61",
              "head_entity_id": "T208",
              "tail_entity_id": "T204"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R62",
              "head_entity_id": "T207",
              "tail_entity_id": "T204"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R63",
              "head_entity_id": "T206",
              "tail_entity_id": "T204"
            }
          ],
          "sentence_en": "3. Reducing PPG is related to improving cardiovascular disease risk factors: Controlling PPG is related to improving multiple cardiovascular disease risk factors, such as lowering TC, TG, LDL-C and increasing HDL-C; lowering blood pressure, hypercoagulable state and inflammatory factors; slowing down the progression of CIMT, etc."
        }
      ],
      "paragraph_en": "3. Reducing PPG is related to improving cardiovascular disease risk factors: Controlling PPG is related to improving multiple cardiovascular disease risk factors, such as lowering TC, TG, LDL-C and increasing HDL-C; lowering blood pressure, hypercoagulable state and inflammatory factors; slowing down the progression of CIMT, etc."
    },
    {
      "paragraph_id": "19",
      "paragraph": "五、餐后高血糖的管理",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "五、餐后高血糖的管理",
          "start_idx": 0,
          "end_idx": 10,
          "entities": [
            {
              "entity_id": "T217",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "5. Management of postprandial hyperglycemia"
        }
      ],
      "paragraph_en": "5. Management of postprandial hyperglycemia"
    },
    {
      "paragraph_id": "20",
      "paragraph": "1.餐后高血糖的控制目标：控制餐后血糖对HbA1c达标及减少血糖波动非常重要。设定HbA1c目标值应根据患者年龄、病程、预期寿命、并发症严重程度、低血糖发生风险等因素个体化确定，与此相对应的PPG控制目标也应遵循个体化原则。(表3)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.餐后高血糖的控制目标：控制餐后血糖对HbA1c达标及减少血糖波动非常重要。设定HbA1c目标值应根据患者年龄、病程、预期寿命、并发症严重程度、低血糖发生风险等因素个体化确定，与此相对应的PPG控制目标也应遵循个体化原则。",
          "start_idx": 0,
          "end_idx": 112,
          "entities": [
            {
              "entity_id": "T218",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T219",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 15,
              "end_idx": 19,
              "entity_en": "Postprandial blood sugar"
            },
            {
              "entity_id": "T220",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 20,
              "end_idx": 25,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T221",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 30,
              "end_idx": 32,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T222",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 32,
              "end_idx": 34,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T223",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 41,
              "end_idx": 46,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T224",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 68,
              "end_idx": 70,
              "entity_en": "serious"
            },
            {
              "entity_id": "T225",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 73,
              "end_idx": 76,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T226",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 95,
              "end_idx": 98,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T227",
              "entity": "达标",
              "entity_type": "Test_Value",
              "start_idx": 25,
              "end_idx": 27,
              "entity_en": "Meet the Standard"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R64",
              "head_entity_id": "T219",
              "tail_entity_id": "T218"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R65",
              "head_entity_id": "T220",
              "tail_entity_id": "T218"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R66",
              "head_entity_id": "T221",
              "tail_entity_id": "T218"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R67",
              "head_entity_id": "T223",
              "tail_entity_id": "T225"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R68",
              "head_entity_id": "T226",
              "tail_entity_id": "T225"
            }
          ],
          "sentence_en": "1. Postprandial hyperglycemia control target: Controlling postprandial blood sugar is very important for achieving HbA1c target and reducing blood sugar fluctuations. The HbA1c target value should be determined individually based on factors such as the patient's age, course of disease, life expectancy, severity of complications, and risk of hypoglycemia. The corresponding PPG control target should also follow the principle of individualization."
        },
        {
          "sentence_id": "1",
          "sentence": "(表3)",
          "start_idx": 112,
          "end_idx": 116,
          "entities": [],
          "relations": [],
          "sentence_en": "(Table 3)"
        }
      ],
      "paragraph_en": "1. Postprandial hyperglycemia control target: Controlling postprandial blood sugar is very important for achieving HbA1c target and reducing blood sugar fluctuations. Setting the HbA1c target value should be determined individually based on factors such as the patient's age, course of disease, life expectancy, severity of complications, and risk of hypoglycemia. The corresponding PPG control target should also follow the principle of individualization. (Table 3)"
    },
    {
      "paragraph_id": "21",
      "paragraph": "2.控制PPG的方法",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.控制PPG的方法",
          "start_idx": 0,
          "end_idx": 10,
          "entities": [
            {
              "entity_id": "T228",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "PPG"
            }
          ],
          "relations": [],
          "sentence_en": "2. Methods for controlling PPG"
        }
      ],
      "paragraph_en": "2. Methods for controlling PPG"
    },
    {
      "paragraph_id": "22",
      "paragraph": "(1)生活方式干预：饮食的质和量均影响PPG。高GI饮食可导致PPG升高，且增加血糖曲线下面积(AUC)。分别摄入低GI饮食与高GI饮食可使HbA1c相差0.5%~0.7%。餐后运动可以降低T2DM患者PPG，降低幅度与运动持续时间和频率密切相关，但较少影响FPG。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)生活方式干预：饮食的质和量均影响PPG。高GI饮食可导致PPG升高，且增加血糖曲线下面积(AUC)。分别摄入低GI饮食与高GI饮食可使HbA1c相差0.5%~0.7%。餐后运动可以降低T2DM患者PPG，降低幅度与运动持续时间和频率密切相关，但较少影响FPG。",
          "start_idx": 0,
          "end_idx": 133,
          "entities": [
            {
              "entity_id": "T229",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 3,
              "end_idx": 9,
              "entity_en": "Lifestyle interventions"
            },
            {
              "entity_id": "T230",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 19,
              "end_idx": 22,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T231",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 31,
              "end_idx": 34,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T232",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 34,
              "end_idx": 36,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T233",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 40,
              "end_idx": 42,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T234",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 70,
              "end_idx": 75,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T235",
              "entity": "相差0.5%~0.7%",
              "entity_type": "Test_Value",
              "start_idx": 75,
              "end_idx": 86,
              "entity_en": "Difference 0.5%~0.7%"
            },
            {
              "entity_id": "T236",
              "entity": "餐后运动",
              "entity_type": "Treatment",
              "start_idx": 87,
              "end_idx": 91,
              "entity_en": "Post-meal exercise"
            },
            {
              "entity_id": "T237",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 95,
              "end_idx": 99,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T238",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 95,
              "end_idx": 97,
              "entity_en": "T2"
            },
            {
              "entity_id": "T239",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 101,
              "end_idx": 104,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T240",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 129,
              "end_idx": 132,
              "entity_en": "FPG"
            }
          ],
          "relations": [
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R69",
              "head_entity_id": "T236",
              "tail_entity_id": "T237"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R70",
              "head_entity_id": "T238",
              "tail_entity_id": "T237"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R71",
              "head_entity_id": "T239",
              "tail_entity_id": "T237"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R72",
              "head_entity_id": "T240",
              "tail_entity_id": "T237"
            }
          ],
          "sentence_en": "(1) Lifestyle intervention: Both the quality and quantity of diet affect PPG. A high GI diet can lead to an increase in PPG and increase the area under the blood glucose curve (AUC). Eating a low GI diet or a high GI diet can cause a 0.5% to 0.7% difference in HbA1c. Postprandial exercise can reduce PPG in patients with T2DM, and the extent of the reduction is closely related to the duration and frequency of exercise, but it has little effect on FPG."
        }
      ],
      "paragraph_en": "(1) Lifestyle intervention: Both the quality and quantity of diet affect PPG. A high GI diet can lead to an increase in PPG and increase the area under the blood glucose curve (AUC). Eating a low GI diet or a high GI diet can cause a 0.5% to 0.7% difference in HbA1c. Postprandial exercise can reduce PPG in patients with T2DM, and the extent of the reduction is closely related to the duration and frequency of exercise, but it has little effect on FPG."
    },
    {
      "paragraph_id": "23",
      "paragraph": "(2)降糖药物：各种降糖药物均能不同程度地降低FPG和PPG，以降低PPG为主的口服降糖药包括α-糖苷酶抑制剂、短效磺脲类促泌剂、格列奈类促泌剂、二肽基肽酶一4(DPP-4)抑制剂；以降低PPG为主的注射制剂包括短效胰岛素及速效胰岛素似物、短效胰升血糖素样肽-1(GLP-1)受体激动剂。(表4)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)降糖药物：各种降糖药物均能不同程度地降低FPG和PPG，以降低PPG为主的口服降糖药包括α-糖苷酶抑制剂、短效磺脲类促泌剂、格列奈类促泌剂、二肽基肽酶一4(DPP-4)抑制剂；以降低PPG为主的注射制剂包括短效胰岛素及速效胰岛素似物、短效胰升血糖素样肽-1(GLP-1)受体激动剂。",
          "start_idx": 0,
          "end_idx": 144,
          "entities": [
            {
              "entity_id": "T241",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 23,
              "end_idx": 26,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T242",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 27,
              "end_idx": 30,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T243",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 34,
              "end_idx": 37,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T244",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 40,
              "end_idx": 42,
              "entity_en": "oral"
            },
            {
              "entity_id": "T245",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 55,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T246",
              "entity": "短效磺脲类促泌剂",
              "entity_type": "Drug",
              "start_idx": 56,
              "end_idx": 64,
              "entity_en": "Short-acting sulfonylurea secretagogues"
            },
            {
              "entity_id": "T247",
              "entity": "格列奈类促泌剂",
              "entity_type": "Drug",
              "start_idx": 65,
              "end_idx": 72,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T248",
              "entity": "二肽基肽酶一4(DPP-4)抑制剂",
              "entity_type": "Drug",
              "start_idx": 73,
              "end_idx": 90,
              "entity_en": "Dipeptidyl peptidase-4 (DPP-4) inhibitors"
            },
            {
              "entity_id": "T249",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 94,
              "end_idx": 97,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T250",
              "entity": "注射",
              "entity_type": "Method",
              "start_idx": 100,
              "end_idx": 102,
              "entity_en": "injection"
            },
            {
              "entity_id": "T251",
              "entity": "短效胰岛素",
              "entity_type": "Drug",
              "start_idx": 106,
              "end_idx": 111,
              "entity_en": "Short-acting insulin"
            },
            {
              "entity_id": "T252",
              "entity": "效胰岛素似物",
              "entity_type": "Drug",
              "start_idx": 113,
              "end_idx": 119,
              "entity_en": "Insulin analogs"
            },
            {
              "entity_id": "T253",
              "entity": "短效胰升血糖素样肽-1(GLP-1)受体激动剂",
              "entity_type": "Drug",
              "start_idx": 120,
              "end_idx": 143,
              "entity_en": "Short-acting glucagon-like peptide-1 (GLP-1) receptor agonists"
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R73",
              "head_entity_id": "T244",
              "tail_entity_id": "T245"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R74",
              "head_entity_id": "T244",
              "tail_entity_id": "T246"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R75",
              "head_entity_id": "T244",
              "tail_entity_id": "T247"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R76",
              "head_entity_id": "T244",
              "tail_entity_id": "T248"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R77",
              "head_entity_id": "T250",
              "tail_entity_id": "T251"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R78",
              "head_entity_id": "T250",
              "tail_entity_id": "T252"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R79",
              "head_entity_id": "T250",
              "tail_entity_id": "T253"
            }
          ],
          "sentence_en": "(2) Hypoglycemic drugs: Various hypoglycemic drugs can reduce FPG and PPG to varying degrees. Oral hypoglycemic drugs that mainly reduce PPG include α-glucosidase inhibitors, short-acting sulfonylurea secretagogues, glinides secretagogues, and dipeptidyl peptidase-4 (DPP-4) inhibitors; injectable preparations that mainly reduce PPG include short-acting insulin and rapid-acting insulin analogs, and short-acting glucagon-like peptide-1 (GLP-1) receptor agonists."
        },
        {
          "sentence_id": "1",
          "sentence": "(表4)",
          "start_idx": 144,
          "end_idx": 148,
          "entities": [],
          "relations": [],
          "sentence_en": "(Table 4)"
        }
      ],
      "paragraph_en": "(2) Hypoglycemic drugs: Various hypoglycemic drugs can reduce FPG and PPG to varying degrees. Oral hypoglycemic drugs that mainly reduce PPG include α-glucosidase inhibitors, short-acting sulfonylurea secretagogues, glinides secretagogues, and dipeptidyl peptidase-4 (DPP-4) inhibitors; injection preparations that mainly reduce PPG include short-acting insulin and rapid-acting insulin analogs, and short-acting glucagon-like peptide-1 (GLP-1) receptor agonists. (Table 4)"
    },
    {
      "paragraph_id": "24",
      "paragraph": "以降低餐后血糖为主的口服降糖药物，α-糖苷酶抑制剂能延缓碳水化合物在小肠上段的吸收，降低餐后高血糖和减少血糖波动，包括阿卡波糖、伏格列波糖和米格列醇。α-糖苷酶抑制剂可降低HbA1c约0.5%。在中国人群中开展的MARCH研究表明，新诊断T2DM患者使用阿卡波糖300mg/d，HbA1c降幅达1.1%(可能包括部分安慰剂效应)并可减低体重。荟萃分析结果显示，在二甲双胍治疗的基础上采用α-糖苷酶抑制剂，改善体重的效果与GLP-1受体激动剂相当。常见的不良反应为胃肠道反应(腹胀、腹泻、恶心、肠道排气增多等)。小剂量开始、逐渐加量可减少胃肠道不良反应。单独使用一般不发生低血糖，甚至可减少反应性低血糖，总体耐受性良好。与其他降糖药物联合使用时可进一步改善血糖并减少体重增加。与胰岛素促泌剂或胰岛素合用时，如果出现低血糖，应采取口服或静脉注射葡萄糖纠正。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "以降低餐后血糖为主的口服降糖药物，α-糖苷酶抑制剂能延缓碳水化合物在小肠上段的吸收，降低餐后高血糖和减少血糖波动，包括阿卡波糖、伏格列波糖和米格列醇。α-糖苷酶抑制剂可降低HbA1c约0.5%。在中国人群中开展的MARCH研究表明，新诊断T2DM患者使用阿卡波糖300mg/d，HbA1c降幅达1.1%(可能包括部分安慰剂效应)并可减低体重。荟萃分析结果显示，在二甲双胍治疗的基础上采用α-糖苷酶抑制剂，改善体重的效果与GLP-1受体激动剂相当。常见的不良反应为胃肠道反应(腹胀、腹泻、恶心、肠道排气增多等)。小剂量开始、逐渐加量可减少胃肠道不良反应。单独使用一般不发生低血糖，甚至可减少反应性低血糖，总体耐受性良好。与其他降糖药物联合使用时可进一步改善血糖并减少体重增加。与胰岛素促泌剂或胰岛素合用时，如果出现低血糖，应采取口服或静脉注射葡萄糖纠正。",
          "start_idx": 0,
          "end_idx": 376,
          "entities": [
            {
              "entity_id": "T254",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 3,
              "end_idx": 7,
              "entity_en": "Postprandial blood sugar"
            },
            {
              "entity_id": "T255",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 10,
              "end_idx": 12,
              "entity_en": "oral"
            },
            {
              "entity_id": "T256",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 25,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T257",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 46,
              "end_idx": 49,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T258",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 52,
              "end_idx": 54,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T259",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 54,
              "end_idx": 56,
              "entity_en": "fluctuation"
            },
            {
              "entity_id": "T260",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 59,
              "end_idx": 63,
              "entity_en": "Acarbose"
            },
            {
              "entity_id": "T261",
              "entity": "伏格列波糖",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 69,
              "entity_en": "Voglibose"
            },
            {
              "entity_id": "T262",
              "entity": "米格列醇",
              "entity_type": "Drug",
              "start_idx": 70,
              "end_idx": 74,
              "entity_en": "Miglitol"
            },
            {
              "entity_id": "T263",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 75,
              "end_idx": 83,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T264",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 86,
              "end_idx": 91,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T265",
              "entity": "0.5%",
              "entity_type": "Test_Value",
              "start_idx": 92,
              "end_idx": 96,
              "entity_en": "0.5%"
            },
            {
              "entity_id": "T266",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 119,
              "end_idx": 123,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T267",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 119,
              "end_idx": 121,
              "entity_en": "T2"
            },
            {
              "entity_id": "T268",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 127,
              "end_idx": 131,
              "entity_en": "Acarbose"
            },
            {
              "entity_id": "T269",
              "entity": "300mg/d",
              "entity_type": "Amount",
              "start_idx": 131,
              "end_idx": 138,
              "entity_en": "300 mg/day"
            },
            {
              "entity_id": "T270",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 139,
              "end_idx": 144,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T271",
              "entity": "降幅达1.1%",
              "entity_type": "Test_Value",
              "start_idx": 144,
              "end_idx": 151,
              "entity_en": "The decline was 1.1%"
            },
            {
              "entity_id": "T272",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 181,
              "end_idx": 185,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T273",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 193,
              "end_idx": 201,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T274",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 210,
              "end_idx": 220,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T275",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 231,
              "end_idx": 236,
              "entity_en": "Gastrointestinal reactions"
            },
            {
              "entity_id": "T276",
              "entity": "腹胀",
              "entity_type": "ADE",
              "start_idx": 237,
              "end_idx": 239,
              "entity_en": "Abdominal bloating"
            },
            {
              "entity_id": "T277",
              "entity": "腹泻",
              "entity_type": "ADE",
              "start_idx": 240,
              "end_idx": 242,
              "entity_en": "diarrhea"
            },
            {
              "entity_id": "T278",
              "entity": "恶心",
              "entity_type": "ADE",
              "start_idx": 243,
              "end_idx": 245,
              "entity_en": "nausea"
            },
            {
              "entity_id": "T279",
              "entity": "肠道排气增多",
              "entity_type": "ADE",
              "start_idx": 246,
              "end_idx": 252,
              "entity_en": "Increased intestinal gas"
            },
            {
              "entity_id": "T280",
              "entity": "胃肠道不良反应",
              "entity_type": "ADE",
              "start_idx": 268,
              "end_idx": 275,
              "entity_en": "Gastrointestinal adverse reactions"
            },
            {
              "entity_id": "T281",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 285,
              "end_idx": 288,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T282",
              "entity": "反应性低血糖",
              "entity_type": "Disease",
              "start_idx": 294,
              "end_idx": 300,
              "entity_en": "Reactive hypoglycemia"
            },
            {
              "entity_id": "T283",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 327,
              "end_idx": 329,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T284",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 332,
              "end_idx": 336,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T285",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 338,
              "end_idx": 344,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T286",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 345,
              "end_idx": 348,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T287",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 356,
              "end_idx": 359,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T288",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 363,
              "end_idx": 365,
              "entity_en": "oral"
            },
            {
              "entity_id": "T289",
              "entity": "静脉注射",
              "entity_type": "Method",
              "start_idx": 366,
              "end_idx": 370,
              "entity_en": "Intravenous injection"
            },
            {
              "entity_id": "T290",
              "entity": "葡萄糖",
              "entity_type": "Drug",
              "start_idx": 370,
              "end_idx": 373,
              "entity_en": "glucose"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R80",
              "head_entity_id": "T254",
              "tail_entity_id": "T257"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R81",
              "head_entity_id": "T255",
              "tail_entity_id": "T256"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R82",
              "head_entity_id": "T256",
              "tail_entity_id": "T257"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R83",
              "head_entity_id": "T258",
              "tail_entity_id": "T257"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R84",
              "head_entity_id": "T260",
              "tail_entity_id": "T257"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R85",
              "head_entity_id": "T261",
              "tail_entity_id": "T257"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R86",
              "head_entity_id": "T262",
              "tail_entity_id": "T257"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R87",
              "head_entity_id": "T267",
              "tail_entity_id": "T266"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R88",
              "head_entity_id": "T268",
              "tail_entity_id": "T266"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R89",
              "head_entity_id": "T270",
              "tail_entity_id": "T266"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R90",
              "head_entity_id": "T269",
              "tail_entity_id": "T268"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R91",
              "head_entity_id": "T285",
              "tail_entity_id": "T287"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R92",
              "head_entity_id": "T286",
              "tail_entity_id": "T287"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R93",
              "head_entity_id": "T290",
              "tail_entity_id": "T287"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R94",
              "head_entity_id": "T288",
              "tail_entity_id": "T290"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R95",
              "head_entity_id": "T289",
              "tail_entity_id": "T290"
            }
          ],
          "sentence_en": "Oral hypoglycemic drugs that mainly reduce postprandial blood sugar, α-glucosidase inhibitors can delay the absorption of carbohydrates in the upper small intestine, reduce postprandial hyperglycemia and reduce blood sugar fluctuations, including acarbose, voglibose and miglitol. α-glucosidase inhibitors can reduce HbA1c by about 0.5%. The MARCH study conducted in the Chinese population showed that newly diagnosed T2DM patients used acarbose 300 mg/d, HbA1c decreased by 1.1% (possibly including part of the placebo effect) and reduced body weight. Meta-analysis results showed that the use of α-glucosidase inhibitors on the basis of metformin treatment has an effect on improving body weight comparable to GLP-1 receptor agonists. Common adverse reactions are gastrointestinal reactions (abdominal distension, diarrhea, nausea, increased intestinal gas, etc.). Starting with a small dose and gradually increasing the dose can reduce gastrointestinal adverse reactions. Hypoglycemia generally does not occur when used alone, and it can even reduce reactive hypoglycemia, and is generally well tolerated. When used in combination with other hypoglycemic drugs, it can further improve blood sugar and reduce weight gain. When used in combination with insulin secretagogues or insulin, if hypoglycemia occurs, it should be corrected with oral or intravenous glucose."
        }
      ],
      "paragraph_en": "Oral hypoglycemic drugs that mainly reduce postprandial blood sugar, α-glucosidase inhibitors can delay the absorption of carbohydrates in the upper small intestine, reduce postprandial hyperglycemia and reduce blood sugar fluctuations, including acarbose, voglibose and miglitol. α-glucosidase inhibitors can reduce HbA1c by about 0.5%. The MARCH study conducted in the Chinese population showed that newly diagnosed T2DM patients used acarbose 300 mg/d, HbA1c decreased by 1.1% (possibly including part of the placebo effect) and reduced body weight. Meta-analysis results showed that the use of α-glucosidase inhibitors on the basis of metformin treatment has an effect on improving body weight comparable to GLP-1 receptor agonists. Common adverse reactions are gastrointestinal reactions (abdominal distension, diarrhea, nausea, increased intestinal gas, etc.). Starting with a small dose and gradually increasing the dose can reduce gastrointestinal adverse reactions. Hypoglycemia generally does not occur when used alone, and it can even reduce reactive hypoglycemia, and is generally well tolerated. When used in combination with other hypoglycemic drugs, it can further improve blood sugar and reduce weight gain. When used in combination with insulin secretagogues or insulin, if hypoglycemia occurs, it should be corrected with oral or intravenous glucose."
    },
    {
      "paragraph_id": "25",
      "paragraph": "短效磺脲类促泌剂通过与胰岛β细胞膜上的磺脲类受体结合，促进胰岛素分泌，增加体内胰岛素水平而降低血糖。常用的短效磺脲类药物包括格列吡嗪和格列喹酮，降低HbA1c约1.0%。磺脲类药物可导致低血糖，更易在老年及肝、肾功能不全的患者中发生。磺脲类药物可增加体重。肾功能不全的患者可考虑选用格列喹酮。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "短效磺脲类促泌剂通过与胰岛β细胞膜上的磺脲类受体结合，促进胰岛素分泌，增加体内胰岛素水平而降低血糖。常用的短效磺脲类药物包括格列吡嗪和格列喹酮，降低HbA1c约1.0%。磺脲类药物可导致低血糖，更易在老年及肝、肾功能不全的患者中发生。磺脲类药物可增加体重。肾功能不全的患者可考虑选用格列喹酮。",
          "start_idx": 0,
          "end_idx": 146,
          "entities": [
            {
              "entity_id": "T291",
              "entity": "短效磺脲类促泌剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 8,
              "entity_en": "Short-acting sulfonylurea secretagogues"
            },
            {
              "entity_id": "T292",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 47,
              "end_idx": 49,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T293",
              "entity": "短效磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 60,
              "entity_en": "Short-acting sulfonylureas"
            },
            {
              "entity_id": "T294",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 62,
              "end_idx": 66,
              "entity_en": "Glipizide"
            },
            {
              "entity_id": "T295",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 67,
              "end_idx": 71,
              "entity_en": "Gliquidone"
            },
            {
              "entity_id": "T296",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 74,
              "end_idx": 79,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T297",
              "entity": "约1.0%",
              "entity_type": "Test_Value",
              "start_idx": 79,
              "end_idx": 84,
              "entity_en": "About 1.0%"
            },
            {
              "entity_id": "T298",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 85,
              "end_idx": 90,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T299",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 93,
              "end_idx": 96,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T300",
              "entity": "肝、肾功能不全",
              "entity_type": "Disease",
              "start_idx": 103,
              "end_idx": 110,
              "entity_en": "Liver and kidney dysfunction"
            },
            {
              "entity_id": "T301",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 103,
              "end_idx": 104,
              "entity_en": "liver"
            },
            {
              "entity_id": "T302",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 105,
              "end_idx": 106,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T303",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 117,
              "end_idx": 122,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T304",
              "entity": "增加体重",
              "entity_type": "ADE",
              "start_idx": 123,
              "end_idx": 127,
              "entity_en": "Gaining weight"
            },
            {
              "entity_id": "T305",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 128,
              "end_idx": 133,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T306",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 128,
              "end_idx": 129,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T307",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 141,
              "end_idx": 145,
              "entity_en": "Gliquidone"
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R96",
              "head_entity_id": "T299",
              "tail_entity_id": "T298"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R97",
              "head_entity_id": "T301",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R98",
              "head_entity_id": "T302",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R99",
              "head_entity_id": "T304",
              "tail_entity_id": "T303"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R100",
              "head_entity_id": "T306",
              "tail_entity_id": "T305"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R101",
              "head_entity_id": "T307",
              "tail_entity_id": "T305"
            }
          ],
          "sentence_en": "Short-acting sulfonylurea secretagogues promote insulin secretion by binding to sulfonylurea receptors on the pancreatic β-cell membrane, increasing insulin levels in the body and lowering blood sugar. Commonly used short-acting sulfonylurea drugs include glipizide and gliclazide, which reduce HbA1c by about 1.0%. Sulfonylurea drugs can cause hypoglycemia, which is more likely to occur in the elderly and patients with liver and kidney dysfunction. Sulfonylurea drugs can increase weight. Patients with renal insufficiency may consider using gliclazide."
        }
      ],
      "paragraph_en": "Short-acting sulfonylurea secretagogues promote insulin secretion by binding to sulfonylurea receptors on the pancreatic β-cell membrane, increasing insulin levels in the body and lowering blood sugar. Commonly used short-acting sulfonylurea drugs include glipizide and gliclazide, which reduce HbA1c by about 1.0%. Sulfonylurea drugs can cause hypoglycemia, which is more likely to occur in the elderly and patients with liver and kidney dysfunction. Sulfonylurea drugs can increase weight. Patients with renal insufficiency may consider using gliclazide."
    },
    {
      "paragraph_id": "26",
      "paragraph": "格列奈类药物降糖机制类似磺脲类，但起效更快，改善胰岛素早相分泌更明显，主要降低PPG，括括瑞格列奈、那格列奈和米格列奈，降低HbA1c0.5%~1.0%。瑞格列奈的降糖作用以促进胰岛素第一时相分泌为主。荟萃分析结果显示，在降低HbA1c方面，瑞格列奈优于安慰剂及磺脲类药物。一项随机对照研究显示，单纯饮食治疗血糖控制不佳的新诊断T2DM患者，那格列奈单药治疗12周后HbA1c较基线降低0.9%(可能包括部分安慰剂效应)，2 hPG亦下降。此类药物需在餐前即刻服用，可单独或与其他非促泌剂类降糖药物联合应用。常见不良反应为低血糖和体重增加，但严重程度较磺脲类药物轻。肾功能不全的患者可选择瑞格列奈。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "格列奈类药物降糖机制类似磺脲类，但起效更快，改善胰岛素早相分泌更明显，主要降低PPG，括括瑞格列奈、那格列奈和米格列奈，降低HbA1c0.5%~1.0%。瑞格列奈的降糖作用以促进胰岛素第一时相分泌为主。荟萃分析结果显示，在降低HbA1c方面，瑞格列奈优于安慰剂及磺脲类药物。一项随机对照研究显示，单纯饮食治疗血糖控制不佳的新诊断T2DM患者，那格列奈单药治疗12周后HbA1c较基线降低0.9%(可能包括部分安慰剂效应)，2 hPG亦下降。此类药物需在餐前即刻服用，可单独或与其他非促泌剂类降糖药物联合应用。常见不良反应为低血糖和体重增加，但严重程度较磺脲类药物轻。肾功能不全的患者可选择瑞格列奈。",
          "start_idx": 0,
          "end_idx": 299,
          "entities": [
            {
              "entity_id": "T308",
              "entity": "格列奈类药物",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 6,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T309",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 15,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T310",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 45,
              "end_idx": 49,
              "entity_en": "Repaglinide"
            },
            {
              "entity_id": "T311",
              "entity": "那格列奈",
              "entity_type": "Drug",
              "start_idx": 50,
              "end_idx": 54,
              "entity_en": "Nateglinide"
            },
            {
              "entity_id": "T312",
              "entity": "米格列奈",
              "entity_type": "Drug",
              "start_idx": 55,
              "end_idx": 59,
              "entity_en": "Mitiglinide"
            },
            {
              "entity_id": "T313",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 62,
              "end_idx": 67,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T314",
              "entity": "0.5%~1.0%",
              "entity_type": "Test_Value",
              "start_idx": 67,
              "end_idx": 76,
              "entity_en": "0.5%~1.0%"
            },
            {
              "entity_id": "T315",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 77,
              "end_idx": 81,
              "entity_en": "Repaglinide"
            },
            {
              "entity_id": "T316",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 113,
              "end_idx": 118,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T317",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 121,
              "end_idx": 125,
              "entity_en": "Repaglinide"
            },
            {
              "entity_id": "T318",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 131,
              "end_idx": 136,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T319",
              "entity": "那格列奈",
              "entity_type": "Drug",
              "start_idx": 171,
              "end_idx": 175,
              "entity_en": "Nateglinide"
            },
            {
              "entity_id": "T320",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 164,
              "end_idx": 168,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T321",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 164,
              "end_idx": 166,
              "entity_en": "T2"
            },
            {
              "entity_id": "T322",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 154,
              "end_idx": 156,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T323",
              "entity": "2 hPG",
              "entity_type": "Test_items",
              "start_idx": 211,
              "end_idx": 216,
              "entity_en": "2 hPG"
            },
            {
              "entity_id": "T324",
              "entity": "下降",
              "entity_type": "Test_Value",
              "start_idx": 217,
              "end_idx": 219,
              "entity_en": "decline"
            },
            {
              "entity_id": "T325",
              "entity": "降低0.9%",
              "entity_type": "Test_Value",
              "start_idx": 191,
              "end_idx": 197,
              "entity_en": "Reduced by 0.9%"
            },
            {
              "entity_id": "T326",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 183,
              "end_idx": 188,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T327",
              "entity": "12周后",
              "entity_type": "Duration",
              "start_idx": 179,
              "end_idx": 183,
              "entity_en": "12 Weeks Later"
            },
            {
              "entity_id": "T328",
              "entity": "非促泌剂类",
              "entity_type": "Drug",
              "start_idx": 240,
              "end_idx": 245,
              "entity_en": "Non-secretase enhancers"
            },
            {
              "entity_id": "T329",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 261,
              "end_idx": 264,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T330",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 265,
              "end_idx": 269,
              "entity_en": "Weight gain"
            },
            {
              "entity_id": "T331",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 271,
              "end_idx": 273,
              "entity_en": "serious"
            },
            {
              "entity_id": "T332",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 276,
              "end_idx": 281,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T333",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 39,
              "end_idx": 42,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T334",
              "entity": "单纯饮食治疗",
              "entity_type": "Treatment",
              "start_idx": 148,
              "end_idx": 154,
              "entity_en": "Diet therapy alone"
            },
            {
              "entity_id": "T335",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 156,
              "end_idx": 160,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T336",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 283,
              "end_idx": 288,
              "entity_en": "Renal insufficiency"
            },
            {
              "entity_id": "T337",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 283,
              "end_idx": 284,
              "entity_en": "kidney"
            },
            {
              "entity_id": "T338",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 294,
              "end_idx": 298,
              "entity_en": "Repaglinide"
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R102",
              "head_entity_id": "T319",
              "tail_entity_id": "T320"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R103",
              "head_entity_id": "T327",
              "tail_entity_id": "T319"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R104",
              "head_entity_id": "T321",
              "tail_entity_id": "T320"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R105",
              "head_entity_id": "T334",
              "tail_entity_id": "T320"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R106",
              "head_entity_id": "T322",
              "tail_entity_id": "T320"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R107",
              "head_entity_id": "T326",
              "tail_entity_id": "T320"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R108",
              "head_entity_id": "T323",
              "tail_entity_id": "T320"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R109",
              "head_entity_id": "T329",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R110",
              "head_entity_id": "T330",
              "tail_entity_id": "T332"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R111",
              "head_entity_id": "T337",
              "tail_entity_id": "T336"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R112",
              "head_entity_id": "T338",
              "tail_entity_id": "T336"
            }
          ],
          "sentence_en": "The hypoglycemic mechanism of meglitinides is similar to that of sulfonylureas, but they take effect faster and improve the early phase of insulin secretion more significantly, mainly reducing PPG, including repaglinide, nateglinide and mitiglinide, reducing HbA1c by 0.5%~1.0%. The hypoglycemic effect of repaglinide is mainly to promote the secretion of insulin in the first phase. The results of meta-analysis showed that repaglinide is superior to placebo and sulfonylurea drugs in reducing HbA1c. A randomized controlled study showed that in newly diagnosed T2DM patients with poor blood sugar control with simple diet therapy, HbA1c decreased by 0.9% compared with baseline after 12 weeks of nateglinide monotherapy (possibly including part of the placebo effect), and 2 hPG also decreased. This type of drug needs to be taken immediately before meals and can be used alone or in combination with other non-secretory hypoglycemic drugs. Common adverse reactions are hypoglycemia and weight gain, but the severity is milder than that of sulfonylurea drugs. Repaglinide can be selected for patients with renal insufficiency."
        }
      ],
      "paragraph_en": "The hypoglycemic mechanism of meglitinides is similar to that of sulfonylureas, but they take effect faster and improve the early phase of insulin secretion more significantly, mainly reducing PPG, including repaglinide, nateglinide and mitiglinide, reducing HbA1c by 0.5%~1.0%. The hypoglycemic effect of repaglinide is mainly to promote the secretion of insulin in the first phase. The results of meta-analysis showed that repaglinide is superior to placebo and sulfonylurea drugs in reducing HbA1c. A randomized controlled study showed that in newly diagnosed T2DM patients with poor blood sugar control with simple diet therapy, HbA1c decreased by 0.9% compared with baseline after 12 weeks of nateglinide monotherapy (possibly including part of the placebo effect), and 2 hPG also decreased. This type of drug needs to be taken immediately before meals and can be used alone or in combination with other non-secretory hypoglycemic drugs. Common adverse reactions are hypoglycemia and weight gain, but the severity is milder than that of sulfonylurea drugs. Repaglinide can be selected for patients with renal insufficiency."
    },
    {
      "paragraph_id": "28",
      "paragraph": "3.降低PPG为主的注射制剂(表4)：胰岛素是T2DM患者降糖治疗的有效手段，短效人胰岛素和速效胰岛素类似物主要用于控制PPG。短效胰岛素一般在餐前15~30min皮下注射；速效胰岛素类似物可在餐前即刻皮下注射，个别情况，如进餐量无法估计可餐后即刻注射，注射后30~60min作用达到高峰。速效胰岛素类似物降糖能力与短效人胰岛素相当，但在模拟生理性胰岛素分泌、降低PPG幅度和低血糖风险方面优于人胰岛素，且餐前即刻注射更为方便，有助于提高治疗依从性。此外，预混胰岛素制剂包含一定比例的短效/速效胰岛素，同样可降低PPG。胰岛素治疗可引起低血糖，并增加体重。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.降低PPG为主的注射制剂(表4)：胰岛素是T2DM患者降糖治疗的有效手段，短效人胰岛素和速效胰岛素类似物主要用于控制PPG。短效胰岛素一般在餐前15~30min皮下注射；速效胰岛素类似物可在餐前即刻皮下注射，个别情况，如进餐量无法估计可餐后即刻注射，注射后30~60min作用达到高峰。速效胰岛素类似物降糖能力与短效人胰岛素相当，但在模拟生理性胰岛素分泌、降低PPG幅度和低血糖风险方面优于人胰岛素，且餐前即刻注射更为方便，有助于提高治疗依从性。此外，预混胰岛素制剂包含一定比例的短效/速效胰岛素，同样可降低PPG。胰岛素治疗可引起低血糖，并增加体重。",
          "start_idx": 0,
          "end_idx": 278,
          "entities": [
            {
              "entity_id": "T339",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T340",
              "entity": "注射",
              "entity_type": "Method",
              "start_idx": 10,
              "end_idx": 12,
              "entity_en": "injection"
            },
            {
              "entity_id": "T341",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 22,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T342",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 27,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T343",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 23,
              "end_idx": 25,
              "entity_en": "T2"
            },
            {
              "entity_id": "T344",
              "entity": "短效人胰岛素",
              "entity_type": "Drug",
              "start_idx": 39,
              "end_idx": 45,
              "entity_en": "Short-acting human insulin"
            },
            {
              "entity_id": "T345",
              "entity": "速效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 46,
              "end_idx": 54,
              "entity_en": "Rapid-acting insulin analogs"
            },
            {
              "entity_id": "T346",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 60,
              "end_idx": 63,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T347",
              "entity": "短效胰岛素",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 69,
              "entity_en": "Short-acting insulin"
            },
            {
              "entity_id": "T348",
              "entity": "速效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 87,
              "end_idx": 95,
              "entity_en": "Rapid-acting insulin analogs"
            },
            {
              "entity_id": "T349",
              "entity": "注射",
              "entity_type": "Method",
              "start_idx": 127,
              "end_idx": 129,
              "entity_en": "injection"
            },
            {
              "entity_id": "T350",
              "entity": "30~60min",
              "entity_type": "Duration",
              "start_idx": 130,
              "end_idx": 138,
              "entity_en": "30~60min"
            },
            {
              "entity_id": "T351",
              "entity": "速效胰岛素类似物",
              "entity_type": "Drug",
              "start_idx": 145,
              "end_idx": 153,
              "entity_en": "Rapid-acting insulin analogs"
            },
            {
              "entity_id": "T352",
              "entity": "短效人胰岛素",
              "entity_type": "Drug",
              "start_idx": 158,
              "end_idx": 164,
              "entity_en": "Short-acting human insulin"
            },
            {
              "entity_id": "T353",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 182,
              "end_idx": 185,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T354",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 188,
              "end_idx": 191,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T355",
              "entity": "人胰岛素",
              "entity_type": "Drug",
              "start_idx": 197,
              "end_idx": 201,
              "entity_en": "Human insulin"
            },
            {
              "entity_id": "T356",
              "entity": "预混胰岛素制剂",
              "entity_type": "Drug",
              "start_idx": 228,
              "end_idx": 235,
              "entity_en": "Premixed insulin preparations"
            },
            {
              "entity_id": "T357",
              "entity": "短效/速效胰岛素",
              "entity_type": "Drug",
              "start_idx": 242,
              "end_idx": 250,
              "entity_en": "Short-acting/rapid-acting insulin"
            },
            {
              "entity_id": "T358",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 256,
              "end_idx": 259,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T359",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 260,
              "end_idx": 263,
              "entity_en": "insulin"
            },
            {
              "entity_id": "T360",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 268,
              "end_idx": 271,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T361",
              "entity": "增加体重",
              "entity_type": "ADE",
              "start_idx": 273,
              "end_idx": 277,
              "entity_en": "Gaining weight"
            },
            {
              "entity_id": "T362",
              "entity": "餐后即刻注射",
              "entity_type": "Method",
              "start_idx": 120,
              "end_idx": 126,
              "entity_en": "Inject immediately after meal"
            },
            {
              "entity_id": "T363",
              "entity": "餐前即刻皮下注射",
              "entity_type": "Method",
              "start_idx": 97,
              "end_idx": 105,
              "entity_en": "Subcutaneous injection immediately before meals"
            },
            {
              "entity_id": "T364",
              "entity": "餐前15~30min皮下注射",
              "entity_type": "Method",
              "start_idx": 72,
              "end_idx": 86,
              "entity_en": "Subcutaneous injection 15-30 minutes before meals"
            },
            {
              "entity_id": "T365",
              "entity": "餐前即刻注射",
              "entity_type": "Method",
              "start_idx": 203,
              "end_idx": 209,
              "entity_en": "Inject immediately before meals"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R113",
              "head_entity_id": "T339",
              "tail_entity_id": "T342"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R114",
              "head_entity_id": "T340",
              "tail_entity_id": "T341"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R115",
              "head_entity_id": "T341",
              "tail_entity_id": "T342"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R116",
              "head_entity_id": "T343",
              "tail_entity_id": "T342"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R117",
              "head_entity_id": "T344",
              "tail_entity_id": "T342"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R118",
              "head_entity_id": "T345",
              "tail_entity_id": "T342"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R119",
              "head_entity_id": "T364",
              "tail_entity_id": "T347"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R120",
              "head_entity_id": "T363",
              "tail_entity_id": "T348"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R121",
              "head_entity_id": "T350",
              "tail_entity_id": "T348"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R122",
              "head_entity_id": "T354",
              "tail_entity_id": "T351"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R123",
              "head_entity_id": "T365",
              "tail_entity_id": "T351"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R124",
              "head_entity_id": "T354",
              "tail_entity_id": "T352"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R125",
              "head_entity_id": "T360",
              "tail_entity_id": "T359"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R126",
              "head_entity_id": "T361",
              "tail_entity_id": "T359"
            }
          ],
          "sentence_en": "3. Injectable preparations that mainly reduce PPG (Table 4): Insulin is an effective means of hypoglycemic treatment for patients with T2DM. Short-acting human insulin and rapid-acting insulin analogs are mainly used to control PPG. Short-acting insulin is generally injected subcutaneously 15 to 30 minutes before a meal; rapid-acting insulin analogs can be injected subcutaneously immediately before a meal. In some cases, if the amount of food cannot be estimated, it can be injected immediately after a meal, and the effect reaches a peak 30 to 60 minutes after injection. Rapid-acting insulin analogs have the same glucose-lowering ability as short-acting human insulin, but are superior to human insulin in simulating physiological insulin secretion, reducing PPG amplitude and hypoglycemia risk, and injection immediately before a meal is more convenient, which helps to improve treatment compliance. In addition, premixed insulin preparations contain a certain proportion of short-acting/rapid-acting insulin, which can also reduce PPG. Insulin therapy can cause hypoglycemia and increase weight."
        }
      ],
      "paragraph_en": "3. Injectable preparations that mainly reduce PPG (Table 4): Insulin is an effective means of hypoglycemic treatment for patients with T2DM. Short-acting human insulin and rapid-acting insulin analogs are mainly used to control PPG. Short-acting insulin is generally injected subcutaneously 15 to 30 minutes before a meal; rapid-acting insulin analogs can be injected subcutaneously immediately before a meal. In some cases, if the amount of food cannot be estimated, it can be injected immediately after a meal, and the effect reaches a peak 30 to 60 minutes after injection. Rapid-acting insulin analogs have the same glucose-lowering ability as short-acting human insulin, but are superior to human insulin in simulating physiological insulin secretion, reducing PPG amplitude and hypoglycemia risk, and injection immediately before a meal is more convenient, which helps to improve treatment compliance. In addition, premixed insulin preparations contain a certain proportion of short-acting/rapid-acting insulin, which can also reduce PPG. Insulin therapy can cause hypoglycemia and increase weight."
    },
    {
      "paragraph_id": "30",
      "paragraph": "六、特殊人群餐后高血糖控制药物的选择",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "六、特殊人群餐后高血糖控制药物的选择",
          "start_idx": 0,
          "end_idx": 18,
          "entities": [
            {
              "entity_id": "T366",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 11,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "VI. Choice of drugs for controlling postprandial hyperglycemia in special populations"
        }
      ],
      "paragraph_en": "VI. Choice of drugs for controlling postprandial hyperglycemia in special populations"
    },
    {
      "paragraph_id": "31",
      "paragraph": "1.老年T2DM患者：已确诊的老年T2DM患者，且HbA1c>7.0%时，需考虑口服单药或联合降糖药物治疗。二甲双胍是治疗T2DM的基础用药，但以降低FPG为主；α-糖苷酶抑制剂或DPP-4抑制剂主要降低PPG，这两种药物都不增加低血糖发生，且耐受性较好。老年T2DM患者在使用胰岛素促泌剂或胰岛之前应认真考虑低血糖的风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.老年T2DM患者：已确诊的老年T2DM患者，且HbA1c>7.0%时，需考虑口服单药或联合降糖药物治疗。二甲双胍是治疗T2DM的基础用药，但以降低FPG为主；α-糖苷酶抑制剂或DPP-4抑制剂主要降低PPG，这两种药物都不增加低血糖发生，且耐受性较好。老年T2DM患者在使用胰岛素促泌剂或胰岛之前应认真考虑低血糖的风险。",
          "start_idx": 0,
          "end_idx": 162,
          "entities": [
            {
              "entity_id": "T367",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 8,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T368",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "T2"
            },
            {
              "entity_id": "T369",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 17,
              "end_idx": 21,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T370",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 17,
              "end_idx": 19,
              "entity_en": "T2"
            },
            {
              "entity_id": "T371",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 25,
              "end_idx": 30,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T372",
              "entity": ">7.0%",
              "entity_type": "Test_Value",
              "start_idx": 30,
              "end_idx": 35,
              "entity_en": ">7.0%"
            },
            {
              "entity_id": "T373",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 40,
              "end_idx": 42,
              "entity_en": "oral"
            },
            {
              "entity_id": "T374",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 54,
              "end_idx": 58,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T375",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 61,
              "end_idx": 65,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T376",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 61,
              "end_idx": 63,
              "entity_en": "T2"
            },
            {
              "entity_id": "T377",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 75,
              "end_idx": 78,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T378",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 81,
              "end_idx": 89,
              "entity_en": "α-Glucosidase inhibitors"
            },
            {
              "entity_id": "T379",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 90,
              "end_idx": 98,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T380",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 102,
              "end_idx": 105,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T381",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 115,
              "end_idx": 118,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T382",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 130,
              "end_idx": 134,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T383",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 130,
              "end_idx": 132,
              "entity_en": "T2"
            },
            {
              "entity_id": "T384",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 139,
              "end_idx": 145,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T385",
              "entity": "胰岛",
              "entity_type": "Drug",
              "start_idx": 146,
              "end_idx": 148,
              "entity_en": "Pancreatic Islets"
            },
            {
              "entity_id": "T386",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 155,
              "end_idx": 158,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R127",
              "head_entity_id": "T368",
              "tail_entity_id": "T367"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R128",
              "head_entity_id": "T370",
              "tail_entity_id": "T369"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R129",
              "head_entity_id": "T371",
              "tail_entity_id": "T369"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R130",
              "head_entity_id": "T374",
              "tail_entity_id": "T375"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R131",
              "head_entity_id": "T376",
              "tail_entity_id": "T375"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R132",
              "head_entity_id": "T377",
              "tail_entity_id": "T375"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R133",
              "head_entity_id": "T383",
              "tail_entity_id": "T382"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R134",
              "head_entity_id": "T384",
              "tail_entity_id": "T382"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R135",
              "head_entity_id": "T385",
              "tail_entity_id": "T382"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R136",
              "head_entity_id": "T386",
              "tail_entity_id": "T384"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R137",
              "head_entity_id": "T386",
              "tail_entity_id": "T385"
            }
          ],
          "sentence_en": "1. Elderly patients with T2DM: For elderly patients with confirmed T2DM and HbA1c>7.0%, oral monotherapy or combined hypoglycemic drug therapy should be considered. Metformin is the basic drug for the treatment of T2DM, but it mainly reduces FPG; α-glucosidase inhibitors or DPP-4 inhibitors mainly reduce PPG. Both drugs do not increase the incidence of hypoglycemia and are well tolerated. Elderly patients with T2DM should seriously consider the risk of hypoglycemia before using insulin secretagogues or islets."
        }
      ],
      "paragraph_en": "1. Elderly patients with T2DM: For elderly patients with confirmed T2DM and HbA1c>7.0%, oral monotherapy or combined hypoglycemic drug therapy should be considered. Metformin is the basic drug for the treatment of T2DM, but it mainly reduces FPG; α-glucosidase inhibitors or DPP-4 inhibitors mainly reduce PPG. Both drugs do not increase the incidence of hypoglycemia and are well tolerated. Elderly patients with T2DM should seriously consider the risk of hypoglycemia before using insulin secretagogues or islets."
    },
    {
      "paragraph_id": "32",
      "paragraph": "2.T2DM合并心血管系统疾病：T2DM合并心血管系统疾病患者PPG较高时可选用α-糖苷酶印制剂、DPP-4抑制剂、格列奈类或短效促泌剂。MeRIA研究证实了阿卡波糖的治疗与T2DM患者的心血管预后改善相关。大型临床研究TECOS、EXAMINE和SAVOR和ELIXA结果分别证实了西格列汀、阿格列汀、沙格列汀和利司那肽与安慰剂比较，不增加心血管不良事件的风险。当HbA1c>9.0%时，可根据患者情况选择联合用药的方案。如果两种口服降糖药物联合治疗3个月以上血糖仍不达标，可考虑起始胰岛素治疗或GLP-1受体激动剂或3种口服降糖药物联合治疗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.T2DM合并心血管系统疾病：T2DM合并心血管系统疾病患者PPG较高时可选用α-糖苷酶印制剂、DPP-4抑制剂、格列奈类或短效促泌剂。MeRIA研究证实了阿卡波糖的治疗与T2DM患者的心血管预后改善相关。",
          "start_idx": 0,
          "end_idx": 104,
          "entities": [
            {
              "entity_id": "T387",
              "entity": "心血管系统疾病",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 15,
              "entity_en": "Cardiovascular system diseases"
            },
            {
              "entity_id": "T388",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 8,
              "end_idx": 11,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T389",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T390",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 4,
              "entity_en": "T2"
            },
            {
              "entity_id": "T391",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 20,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T392",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 16,
              "end_idx": 18,
              "entity_en": "T2"
            },
            {
              "entity_id": "T393",
              "entity": "心血管系统疾病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 29,
              "entity_en": "Cardiovascular system diseases"
            },
            {
              "entity_id": "T394",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 22,
              "end_idx": 25,
              "entity_en": "Cardiovascular"
            },
            {
              "entity_id": "T395",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 31,
              "end_idx": 34,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T396",
              "entity": "较高",
              "entity_type": "Test_Value",
              "start_idx": 34,
              "end_idx": 36,
              "entity_en": "Higher"
            },
            {
              "entity_id": "T397",
              "entity": "α-糖苷酶印制剂",
              "entity_type": "Drug",
              "start_idx": 40,
              "end_idx": 48,
              "entity_en": "α-Glucosidase printing agent"
            },
            {
              "entity_id": "T398",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 57,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T399",
              "entity": "格列奈类",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 62,
              "entity_en": "Meglitinides"
            },
            {
              "entity_id": "T400",
              "entity": "短效促泌剂",
              "entity_type": "Drug",
              "start_idx": 63,
              "end_idx": 68,
              "entity_en": "Short-acting secretagogues"
            },
            {
              "entity_id": "T401",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 79,
              "end_idx": 83,
              "entity_en": "Acarbose"
            },
            {
              "entity_id": "T402",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 87,
              "end_idx": 91,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T403",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 87,
              "end_idx": 89,
              "entity_en": "T2"
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R138",
              "head_entity_id": "T388",
              "tail_entity_id": "T387"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R139",
              "head_entity_id": "T390",
              "tail_entity_id": "T389"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R140",
              "head_entity_id": "T392",
              "tail_entity_id": "T391"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R141",
              "head_entity_id": "T395",
              "tail_entity_id": "T391"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R142",
              "head_entity_id": "T397",
              "tail_entity_id": "T391"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R143",
              "head_entity_id": "T398",
              "tail_entity_id": "T391"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R144",
              "head_entity_id": "T399",
              "tail_entity_id": "T391"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R145",
              "head_entity_id": "T400",
              "tail_entity_id": "T391"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R146",
              "head_entity_id": "T394",
              "tail_entity_id": "T393"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R147",
              "head_entity_id": "T401",
              "tail_entity_id": "T402"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R148",
              "head_entity_id": "T403",
              "tail_entity_id": "T402"
            }
          ],
          "sentence_en": "2. T2DM combined with cardiovascular diseases: When the PPG of patients with T2DM combined with cardiovascular diseases is high, α-glucosidase inhibitors, DPP-4 inhibitors, glinides or short-acting secretagogues can be used. The MeRIA study confirmed that acarbose treatment is associated with improved cardiovascular prognosis in patients with T2DM."
        },
        {
          "sentence_id": "1",
          "sentence": "大型临床研究TECOS、EXAMINE和SAVOR和ELIXA结果分别证实了西格列汀、阿格列汀、沙格列汀和利司那肽与安慰剂比较，不增加心血管不良事件的风险。",
          "start_idx": 104,
          "end_idx": 182,
          "entities": [
            {
              "entity_id": "T404",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 42,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T405",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 43,
              "end_idx": 47,
              "entity_en": "Alogliptin"
            },
            {
              "entity_id": "T406",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 48,
              "end_idx": 52,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T407",
              "entity": "利司那肽",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57,
              "entity_en": "Lixisenatide"
            },
            {
              "entity_id": "T408",
              "entity": "心血管不良事件",
              "entity_type": "ADE",
              "start_idx": 67,
              "end_idx": 74,
              "entity_en": "Adverse cardiovascular events"
            }
          ],
          "relations": [],
          "sentence_en": "The results of large-scale clinical studies TECOS, EXAMINE, SAVOR and ELIXA respectively confirmed that sitagliptin, alogliptin, saxagliptin and lixisenatide did not increase the risk of adverse cardiovascular events compared with placebo."
        },
        {
          "sentence_id": "2",
          "sentence": "当HbA1c>9.0%时，可根据患者情况选择联合用药的方案。",
          "start_idx": 182,
          "end_idx": 212,
          "entities": [
            {
              "entity_id": "T409",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 1,
              "end_idx": 6,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T410",
              "entity": ">9.0%",
              "entity_type": "Test_Value",
              "start_idx": 6,
              "end_idx": 11,
              "entity_en": ">9.0%"
            }
          ],
          "relations": [],
          "sentence_en": "When HbA1c>9.0%, a combination medication regimen can be selected according to the patient's condition."
        },
        {
          "sentence_id": "3",
          "sentence": "如果两种口服降糖药物联合治疗3个月以上血糖仍不达标，可考虑起始胰岛素治疗或GLP-1受体激动剂或3种口服降糖药物联合治疗。",
          "start_idx": 212,
          "end_idx": 273,
          "entities": [
            {
              "entity_id": "T411",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 4,
              "end_idx": 6,
              "entity_en": "oral"
            },
            {
              "entity_id": "T412",
              "entity": "3个月以上",
              "entity_type": "Duration",
              "start_idx": 14,
              "end_idx": 19,
              "entity_en": "3 months and above"
            },
            {
              "entity_id": "T413",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 19,
              "end_idx": 21,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T414",
              "entity": "不达标",
              "entity_type": "Test_Value",
              "start_idx": 22,
              "end_idx": 25,
              "entity_en": "Not up to standard"
            },
            {
              "entity_id": "T415",
              "entity": "起始胰岛素",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 34,
              "entity_en": "Starting insulin"
            },
            {
              "entity_id": "T416",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 47,
              "entity_en": "GLP-1 receptor agonists"
            },
            {
              "entity_id": "T417",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 50,
              "end_idx": 52,
              "entity_en": "oral"
            }
          ],
          "relations": [],
          "sentence_en": "If blood sugar levels do not meet target after combined treatment with two oral glucose-lowering drugs for more than three months, consideration may be given to initiating insulin therapy or a GLP-1 receptor agonist or a combination of three oral glucose-lowering drugs."
        }
      ],
      "paragraph_en": "2. T2DM combined with cardiovascular diseases: When the PPG of patients with T2DM combined with cardiovascular diseases is high, α-glucosidase printing agents, DPP-4 inhibitors, glinides or short-acting secretagogues can be used. The MeRIA study confirmed that the treatment of acarbose is associated with improved cardiovascular prognosis in patients with T2DM. The results of large-scale clinical studies TECOS, EXAMINE, SAVOR and ELIXA respectively confirmed that sitagliptin, alogliptin, saxagliptin and lixisenatide did not increase the risk of adverse cardiovascular events compared with placebo. When HbA1c>9.0%, a combination of medications can be selected according to the patient's condition. If blood sugar is still not up to standard after combined treatment of two oral hypoglycemic drugs for more than 3 months, initial insulin treatment or GLP-1 receptor agonists or a combination of three oral hypoglycemic drugs can be considered."
    },
    {
      "paragraph_id": "3",
      "paragraph": "餐后高血糖的定义为摄食后1~2 hPG>7.8mmol/L。餐后高血糖的主要病理生理基础与第一时相/早相胰岛素分泌缺陷、外周组织IS下降、胰升血糖素分泌在进餐后不受抑制及餐后肝糖输出持续增高相关。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "餐后高血糖的定义为摄食后1~2 hPG>7.8mmol/L。",
          "start_idx": 0,
          "end_idx": 30,
          "entities": [
            {
              "entity_id": "T418",
              "entity": ">7.8mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 19,
              "end_idx": 29,
              "entity_en": ">7.8mmol/L"
            },
            {
              "entity_id": "T419",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T421",
              "entity": "1~2 hPG",
              "entity_type": "Test_items",
              "start_idx": 12,
              "end_idx": 19,
              "entity_en": "1~2 hPG"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R149",
              "head_entity_id": "T421",
              "tail_entity_id": "T419"
            }
          ],
          "sentence_en": "Postprandial hyperglycemia is defined as PG>7.8mmol/L 1~2 h after ingestion."
        },
        {
          "sentence_id": "1",
          "sentence": "餐后高血糖的主要病理生理基础与第一时相/早相胰岛素分泌缺陷、外周组织IS下降、胰升血糖素分泌在进餐后不受抑制及餐后肝糖输出持续增高相关。",
          "start_idx": 30,
          "end_idx": 98,
          "entities": [
            {
              "entity_id": "T420",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 5,
              "entity_en": "High blood sugar"
            }
          ],
          "relations": [],
          "sentence_en": "The main pathophysiological basis of postprandial hyperglycemia is related to defective first-phase/early-phase insulin secretion, decreased peripheral tissue IS, uninhibited glucagon secretion after meals, and continued increase in postprandial hepatic glucose output."
        }
      ],
      "paragraph_en": "Postprandial hyperglycemia is defined as PG>7.8mmol/L 1-2 h after eating. The main pathophysiological basis of postprandial hyperglycemia is related to the defect of first phase/early phase insulin secretion, the decrease of peripheral tissue IS, the uninhibited secretion of glucagon after meals and the continuous increase of postprandial hepatic glucose output."
    },
    {
      "paragraph_id": "27",
      "paragraph": "DPP-4抑制剂通过抑制DDP-4酶对GLP-1的降解，提高周围血GLP-1水平2~3倍，进而促进胰岛β细胞分泌胰岛素，抑制胰升血糖素，降低PPG，可降低HbA1c0.4%~0.9%。此类药包括西格列汀、沙格列汀、维格列汀、利格列汀和阿格列汀。中国T2DM患者使用西格列汀单药治疗HbA1c下降0.7%，2 hPG下降2.8mmol/L；单独使用沙格列汀可使HbA1c下降0.5%，以速食面进行混合餐耐量试验(MMTT)可使2 hPG下降1.32mmol/L。同时，二甲双胍单药治疗血糖控不佳的T2DM患者，加用维格列汀后，较安慰剂组HbA1c下降0.51%；2 hPG下降1.53mmol/L。二甲双胍联合磺脲类药物治疗血糖控制不佳的T2DM患者加用利格列汀后，HbA1c较基线下降0.68%。DPP-4酶抑制剂单独使用低血糖风小，对体重的作用为中性或轻度增加。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "DPP-4抑制剂通过抑制DDP-4酶对GLP-1的降解，提高周围血GLP-1水平2~3倍，进而促进胰岛β细胞分泌胰岛素，抑制胰升血糖素，降低PPG，可降低HbA1c0.4%~0.9%。此类药包括西格列汀、沙格列汀、维格列汀、利格列汀和阿格列汀。中国T2DM患者使用西格列汀单药治疗HbA1c下降0.7%，2 hPG下降2.8mmol/L；单独使用沙格列汀可使HbA1c下降0.5%，以速食面进行混合餐耐量试验(MMTT)可使2 hPG下降1.32mmol/L。同时，二甲双胍单药治疗血糖控不佳的T2DM患者，加用维格列汀后，较安慰剂组HbA1c下降0.51%；2 hPG下降1.53mmol/L。二甲双胍联合磺脲类药物治疗血糖控制不佳的T2DM患者加用利格列汀后，HbA1c较基线下降0.68%。DPP-4酶抑制剂单独使用低血糖风小，对体重的作用为中性或轻度增加。",
          "start_idx": 0,
          "end_idx": 382,
          "entities": [
            {
              "entity_id": "T422",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 8,
              "entity_en": "DPP-4 inhibitors"
            },
            {
              "entity_id": "T423",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 70,
              "end_idx": 73,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T424",
              "entity": "降低",
              "entity_type": "Test_Value",
              "start_idx": 68,
              "end_idx": 70,
              "entity_en": "reduce"
            },
            {
              "entity_id": "T425",
              "entity": "降低",
              "entity_type": "Test_Value",
              "start_idx": 75,
              "end_idx": 77,
              "entity_en": "reduce"
            },
            {
              "entity_id": "T426",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 77,
              "end_idx": 82,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T427",
              "entity": "0.4%~0.9%",
              "entity_type": "Test_Value",
              "start_idx": 82,
              "end_idx": 91,
              "entity_en": "0.4%~0.9%"
            },
            {
              "entity_id": "T428",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 97,
              "end_idx": 101,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T429",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 102,
              "end_idx": 106,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T430",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 107,
              "end_idx": 111,
              "entity_en": "Vildagliptin"
            },
            {
              "entity_id": "T431",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 112,
              "end_idx": 116,
              "entity_en": "Linagliptin"
            },
            {
              "entity_id": "T432",
              "entity": "阿格列汀",
              "entity_type": "Drug",
              "start_idx": 117,
              "end_idx": 121,
              "entity_en": "Alogliptin"
            },
            {
              "entity_id": "T433",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 124,
              "end_idx": 128,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T434",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 124,
              "end_idx": 126,
              "entity_en": "T2"
            },
            {
              "entity_id": "T435",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 132,
              "end_idx": 136,
              "entity_en": "Sitagliptin"
            },
            {
              "entity_id": "T436",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 140,
              "end_idx": 145,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T437",
              "entity": "下降0.7%",
              "entity_type": "Test_Value",
              "start_idx": 145,
              "end_idx": 151,
              "entity_en": "Down 0.7%"
            },
            {
              "entity_id": "T438",
              "entity": "2 hPG",
              "entity_type": "Test_items",
              "start_idx": 152,
              "end_idx": 157,
              "entity_en": "2 hPG"
            },
            {
              "entity_id": "T439",
              "entity": "下降2.8mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 157,
              "end_idx": 168,
              "entity_en": "Decreased by 2.8mmol/L"
            },
            {
              "entity_id": "T440",
              "entity": "沙格列汀",
              "entity_type": "Drug",
              "start_idx": 173,
              "end_idx": 177,
              "entity_en": "Saxagliptin"
            },
            {
              "entity_id": "T441",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 179,
              "end_idx": 184,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T442",
              "entity": "下降0.5%",
              "entity_type": "Test_Value",
              "start_idx": 184,
              "end_idx": 190,
              "entity_en": "Down 0.5%"
            },
            {
              "entity_id": "T443",
              "entity": "2 hPG",
              "entity_type": "Test_items",
              "start_idx": 212,
              "end_idx": 217,
              "entity_en": "2 hPG"
            },
            {
              "entity_id": "T444",
              "entity": "下降1.32mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 217,
              "end_idx": 229,
              "entity_en": "Decreased by 1.32mmol/L"
            },
            {
              "entity_id": "T445",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 233,
              "end_idx": 237,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T446",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 241,
              "end_idx": 243,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T447",
              "entity": "控不佳",
              "entity_type": "Test_Value",
              "start_idx": 243,
              "end_idx": 246,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T448",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 247,
              "end_idx": 251,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T449",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 247,
              "end_idx": 249,
              "entity_en": "T2"
            },
            {
              "entity_id": "T450",
              "entity": "维格列汀",
              "entity_type": "Drug",
              "start_idx": 256,
              "end_idx": 260,
              "entity_en": "Vildagliptin"
            },
            {
              "entity_id": "T451",
              "entity": "安慰剂",
              "entity_type": "Drug",
              "start_idx": 263,
              "end_idx": 266,
              "entity_en": "Placebo"
            },
            {
              "entity_id": "T452",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 267,
              "end_idx": 272,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T453",
              "entity": "下降0.51%",
              "entity_type": "Test_Value",
              "start_idx": 272,
              "end_idx": 279,
              "entity_en": "Down 0.51%"
            },
            {
              "entity_id": "T454",
              "entity": "2 hPG",
              "entity_type": "Test_items",
              "start_idx": 280,
              "end_idx": 285,
              "entity_en": "2 hPG"
            },
            {
              "entity_id": "T455",
              "entity": "下降1.53mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 285,
              "end_idx": 297,
              "entity_en": "Decreased by 1.53mmol/L"
            },
            {
              "entity_id": "T456",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 298,
              "end_idx": 302,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T457",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 304,
              "end_idx": 309,
              "entity_en": "Sulfonylureas"
            },
            {
              "entity_id": "T458",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 311,
              "end_idx": 313,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T459",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 313,
              "end_idx": 317,
              "entity_en": "Poor control"
            },
            {
              "entity_id": "T460",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 318,
              "end_idx": 322,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T461",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 318,
              "end_idx": 320,
              "entity_en": "T2"
            },
            {
              "entity_id": "T462",
              "entity": "利格列汀",
              "entity_type": "Drug",
              "start_idx": 326,
              "end_idx": 330,
              "entity_en": "Linagliptin"
            },
            {
              "entity_id": "T463",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 332,
              "end_idx": 337,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T464",
              "entity": "下降0.68%",
              "entity_type": "Test_Value",
              "start_idx": 340,
              "end_idx": 347,
              "entity_en": "Down 0.68%"
            },
            {
              "entity_id": "T465",
              "entity": "DPP-4酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 348,
              "end_idx": 357,
              "entity_en": "DPP-4 enzyme inhibitors"
            },
            {
              "entity_id": "T466",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 361,
              "end_idx": 364,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T467",
              "entity": "体重的作用为中性或轻度增加",
              "entity_type": "ADE",
              "start_idx": 368,
              "end_idx": 381,
              "entity_en": "Effect on body weight is neutral or mild"
            },
            {
              "entity_id": "T468",
              "entity": "混合餐耐量试验(MMTT)",
              "entity_type": "Test",
              "start_idx": 197,
              "end_idx": 210,
              "entity_en": "Mixed meal tolerance test (MMTT)"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R150",
              "head_entity_id": "T434",
              "tail_entity_id": "T433"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R151",
              "head_entity_id": "T435",
              "tail_entity_id": "T433"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R152",
              "head_entity_id": "T440",
              "tail_entity_id": "T433"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R153",
              "head_entity_id": "T436",
              "tail_entity_id": "T433"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R154",
              "head_entity_id": "T438",
              "tail_entity_id": "T433"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R155",
              "head_entity_id": "T445",
              "tail_entity_id": "T448"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R156",
              "head_entity_id": "T446",
              "tail_entity_id": "T448"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R157",
              "head_entity_id": "T449",
              "tail_entity_id": "T448"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R158",
              "head_entity_id": "T450",
              "tail_entity_id": "T448"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R159",
              "head_entity_id": "T451",
              "tail_entity_id": "T448"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R160",
              "head_entity_id": "T452",
              "tail_entity_id": "T448"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R161",
              "head_entity_id": "T454",
              "tail_entity_id": "T448"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R162",
              "head_entity_id": "T456",
              "tail_entity_id": "T460"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R163",
              "head_entity_id": "T457",
              "tail_entity_id": "T460"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R164",
              "head_entity_id": "T458",
              "tail_entity_id": "T460"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R165",
              "head_entity_id": "T461",
              "tail_entity_id": "T460"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R166",
              "head_entity_id": "T462",
              "tail_entity_id": "T460"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R167",
              "head_entity_id": "T467",
              "tail_entity_id": "T465"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R168",
              "head_entity_id": "T466",
              "tail_entity_id": "T465"
            }
          ],
          "sentence_en": "DPP-4 inhibitors increase peripheral blood GLP-1 levels by 2 to 3 times by inhibiting the degradation of GLP-1 by DDP-4 enzyme, thereby promoting insulin secretion from pancreatic β cells, inhibiting glucagon, reducing PPG, and reducing HbA1c by 0.4% to 0.9%. This type of drug includes sitagliptin, saxagliptin, vildagliptin, linagliptin and alogliptin. Chinese T2DM patients treated with sitagliptin alone had a 0.7% decrease in HbA1c and a 2.8 mmol/L decrease in 2 hPG; saxagliptin alone could reduce HbA1c by 0.5%, and a mixed meal tolerance test (MMTT) with instant noodles could reduce 2 hPG by 1.32 mmol/L. At the same time, T2DM patients with poor blood sugar control treated with metformin alone, after adding vildagliptin, had a 0.51% decrease in HbA1c compared with the placebo group; 2 hPG decreased by 1.53 mmol/L. When linagliptin was added to metformin combined with sulfonylureas to treat T2DM patients with poor glycemic control, HbA1c decreased by 0.68% from baseline. DPP-4 enzyme inhibitors alone have a low risk of hypoglycemia and a neutral or mild increase in body weight."
        }
      ],
      "paragraph_en": "DPP-4 inhibitors increase peripheral blood GLP-1 levels by 2 to 3 times by inhibiting the degradation of GLP-1 by DDP-4 enzymes, thereby promoting insulin secretion from pancreatic β cells, inhibiting glucagon, and reducing PPG, which can reduce HbA1c by 0.4% to 0.9%. This type of drug includes sitagliptin, saxagliptin, vildagliptin, linagliptin, and alogliptin. In Chinese T2DM patients, HbA1c decreased by 0.7% and 2 hPG decreased by 2.8mmol/L using sitagliptin alone; saxagliptin alone can reduce HbA1c by 0.5%, and a mixed meal tolerance test (MMTT) with instant noodles can reduce 2 hPG by 1.32mmol/L. At the same time, T2DM patients with poor blood sugar control who were treated with metformin alone had a 0.51% decrease in HbA1c and a 1.53mmol/L decrease in 2 hPG after adding vildagliptin compared with the placebo group. When linagliptin was added to metformin combined with sulfonylureas to treat T2DM patients with poor glycemic control, HbA1c decreased by 0.68% from baseline. DPP-4 enzyme inhibitors alone have a low risk of hypoglycemia and a neutral or mild increase in body weight."
    },
    {
      "paragraph_id": "29",
      "paragraph": "短效GLP-1受体激动剂可刺激胰岛素分泌、抑制胰升血糖素分泌、延缓胃排空、增加饱腹感和减少进食量而降低PPG。目前，我国临床使用的短效制剂艾塞那肽。在二甲双胍治疗的基础上联合短效GLP-1受体激动剂可降低HbA1c0.8%~1.5%。我国新诊断T2DM患者使用艾塞那肽治疗后，HbA1c较基线下降1.8%。其显著的特点是，在降糖同时，大部分患者可减轻体重、降低TG和SBP。常见的不良反应为胃肠道反应，如恶心、呕吐等，但随着治疗时间(约2周)延长逐渐减弱。单用低血糖发生率低，与胰岛素促泌剂合用可增加低血糖发生风险。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "短效GLP-1受体激动剂可刺激胰岛素分泌、抑制胰升血糖素分泌、延缓胃排空、增加饱腹感和减少进食量而降低PPG。目前，我国临床使用的短效制剂艾塞那肽。在二甲双胍治疗的基础上联合短效GLP-1受体激动剂可降低HbA1c0.8%~1.5%。我国新诊断T2DM患者使用艾塞那肽治疗后，HbA1c较基线下降1.8%。其显著的特点是，在降糖同时，大部分患者可减轻体重、降低TG和SBP。常见的不良反应为胃肠道反应，如恶心、呕吐等，但随着治疗时间(约2周)延长逐渐减弱。单用低血糖发生率低，与胰岛素促泌剂合用可增加低血糖发生风险。",
          "start_idx": 0,
          "end_idx": 258,
          "entities": [
            {
              "entity_id": "T469",
              "entity": "短效GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 12,
              "entity_en": "Short-acting GLP-1 receptor agonists"
            },
            {
              "entity_id": "T470",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 51,
              "end_idx": 54,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T471",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 69,
              "end_idx": 73,
              "entity_en": "Exenatide"
            },
            {
              "entity_id": "T472",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 75,
              "end_idx": 79,
              "entity_en": "Metformin"
            },
            {
              "entity_id": "T473",
              "entity": "短效GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 87,
              "end_idx": 99,
              "entity_en": "Short-acting GLP-1 receptor agonists"
            },
            {
              "entity_id": "T474",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 102,
              "end_idx": 107,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T475",
              "entity": "0.8%~1.5%",
              "entity_type": "Test_Value",
              "start_idx": 107,
              "end_idx": 116,
              "entity_en": "0.8%~1.5%"
            },
            {
              "entity_id": "T476",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 122,
              "end_idx": 126,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T477",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 122,
              "end_idx": 124,
              "entity_en": "T2"
            },
            {
              "entity_id": "T478",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 130,
              "end_idx": 134,
              "entity_en": "Exenatide"
            },
            {
              "entity_id": "T479",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 138,
              "end_idx": 143,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T480",
              "entity": "下降1.8%",
              "entity_type": "Test_Value",
              "start_idx": 146,
              "end_idx": 152,
              "entity_en": "Down 1.8%"
            },
            {
              "entity_id": "T481",
              "entity": "TG",
              "entity_type": "Test_items",
              "start_idx": 180,
              "end_idx": 182,
              "entity_en": "TG"
            },
            {
              "entity_id": "T482",
              "entity": "SBP",
              "entity_type": "Test_items",
              "start_idx": 183,
              "end_idx": 186,
              "entity_en": "SBP"
            },
            {
              "entity_id": "T483",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 195,
              "end_idx": 200,
              "entity_en": "Gastrointestinal reactions"
            },
            {
              "entity_id": "T484",
              "entity": "恶心",
              "entity_type": "ADE",
              "start_idx": 202,
              "end_idx": 204,
              "entity_en": "nausea"
            },
            {
              "entity_id": "T485",
              "entity": "呕吐",
              "entity_type": "ADE",
              "start_idx": 205,
              "end_idx": 207,
              "entity_en": "Vomit"
            },
            {
              "entity_id": "T486",
              "entity": "约2周",
              "entity_type": "Duration",
              "start_idx": 217,
              "end_idx": 220,
              "entity_en": "About 2 weeks"
            },
            {
              "entity_id": "T487",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 230,
              "end_idx": 233,
              "entity_en": "Hypoglycemia"
            },
            {
              "entity_id": "T488",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 239,
              "end_idx": 245,
              "entity_en": "Insulin secretagogues"
            },
            {
              "entity_id": "T489",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 250,
              "end_idx": 253,
              "entity_en": "Hypoglycemia"
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R169",
              "head_entity_id": "T477",
              "tail_entity_id": "T476"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R170",
              "head_entity_id": "T478",
              "tail_entity_id": "T476"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R171",
              "head_entity_id": "T479",
              "tail_entity_id": "T476"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R172",
              "head_entity_id": "T487",
              "tail_entity_id": "T488"
            }
          ],
          "sentence_en": "Short-acting GLP-1 receptor agonists can stimulate insulin secretion, inhibit glucagon secretion, delay gastric emptying, increase satiety and reduce food intake to reduce PPG. At present, the short-acting preparation exenatide is used clinically in my country. Combining short-acting GLP-1 receptor agonists with metformin treatment can reduce HbA1c by 0.8%~1.5%. After exenatide treatment, HbA1c of newly diagnosed T2DM patients in my country decreased by 1.8% compared with baseline. Its notable feature is that while lowering blood sugar, most patients can lose weight, reduce TG and SBP. Common adverse reactions are gastrointestinal reactions, such as nausea and vomiting, but they gradually weaken as the treatment time (about 2 weeks) is prolonged. The incidence of hypoglycemia is low when used alone, and the risk of hypoglycemia can be increased when used in combination with insulin secretagogues."
        }
      ],
      "paragraph_en": "Short-acting GLP-1 receptor agonists can stimulate insulin secretion, inhibit glucagon secretion, delay gastric emptying, increase satiety and reduce food intake to reduce PPG. At present, the short-acting preparation exenatide is used clinically in my country. Combining short-acting GLP-1 receptor agonists with metformin treatment can reduce HbA1c by 0.8%~1.5%. After exenatide treatment, HbA1c of newly diagnosed T2DM patients in my country decreased by 1.8% compared with baseline. Its notable feature is that while lowering blood sugar, most patients can lose weight, reduce TG and SBP. Common adverse reactions are gastrointestinal reactions, such as nausea and vomiting, but they gradually weaken as the treatment time (about 2 weeks) is prolonged. The incidence of hypoglycemia is low when used alone, and the risk of hypoglycemia can be increased when used in combination with insulin secretagogues."
    },
    {
      "paragraph_id": "1",
      "paragraph": "中国成人糖尿病患病率高达9.7%，患者人数居全球首位。糖尿病防治的关键在于积极预防、早期诊断及尽早规范化干预。糖尿病管理的最终目标是防治糖尿病慢性并发症，包括微血管并发症和动脉粥样硬化性血管病(ASVD)，以提高患者生活质量、延长寿命。研究显示，我国门诊T2DM患者血糖达标率仅32.6%；在心血管风险因素控制方面，我国T2DM患者血糖、血压、血脂达标率分别为47.7%、28.4%和36.1%，仅5.6%的患者3项指标均达标。目前，我国糖尿病患者血糖控制现状及临床合理用药情况不容乐观。大部分中国T2DM患者伴有餐后血糖(PPG)升高。流行病学筛查诊断的糖尿病患者中，单纯PPG升高患者的比例达50%，糖尿病前期中约70%为单纯性IGT。PPG增高是导致HbA1c升高的主要原因之一，PPG升高与糖尿病慢性并发症发生发展有相关性。因此，控制PPG是促使HbA1c控制达标以防治糖尿病慢性发症的重要策略。糖尿病的管理中，控制PPG的手段与控制FPG的策略和手段有明显不同。为使广大从事糖尿病防治的医务人员更全面了解餐后高血糖的病理生理特征、临床意义和更好地应用针对餐后高血糖的控制措施，国内部分专家基于国内外临床证据及临床经验，制订了《中国2型糖尿病患者餐后高血糖管理专家共识》，以期为临床医生更好地管理糖尿病提供参考。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "中国成人糖尿病患病率高达9.7%，患者人数居全球首位。糖尿病防治的关键在于积极预防、早期诊断及尽早规范化干预。糖尿病管理的最终目标是防治糖尿病慢性并发症，包括微血管并发症和动脉粥样硬化性血管病(ASVD)，以提高患者生活质量、延长寿命。研究显示，我国门诊T2DM患者血糖达标率仅32.6%；在心血管风险因素控制方面，我国T2DM患者血糖、血压、血脂达标率分别为47.7%、28.4%和36.1%，仅5.6%的患者3项指标均达标。目前，我国糖尿病患者血糖控制现状及临床合理用药情况不容乐观。大部分中国T2DM患者伴有餐后血糖(PPG)升高。流行病学筛查诊断的糖尿病患者中，单纯PPG升高患者的比例达50%，糖尿病前期中约70%为单纯性IGT。PPG增高是导致HbA1c升高的主要原因之一，PPG升高与糖尿病慢性并发症发生发展有相关性。因此，控制PPG是促使HbA1c控制达标以防治糖尿病慢性发症的重要策略。糖尿病的管理中，控制PPG的手段与控制FPG的策略和手段有明显不同。为使广大从事糖尿病防治的医务人员更全面了解餐后高血糖的病理生理特征、临床意义和更好地应用针对餐后高血糖的控制措施，国内部分专家基于国内外临床证据及临床经验，制订了《中国2型糖尿病患者餐后高血糖管理专家共识》，以期为临床医生更好地管理糖尿病提供参考。",
          "start_idx": 0,
          "end_idx": 560,
          "entities": [
            {
              "entity_id": "T490",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T491",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 30,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T492",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 55,
              "end_idx": 58,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T493",
              "entity": "微血管并发症",
              "entity_type": "Disease",
              "start_idx": 79,
              "end_idx": 85,
              "entity_en": "Microvascular complications"
            },
            {
              "entity_id": "T494",
              "entity": "动脉粥样硬化性血管病(ASVD)",
              "entity_type": "Disease",
              "start_idx": 86,
              "end_idx": 102,
              "entity_en": "Atherosclerotic vascular disease (ASVD)"
            },
            {
              "entity_id": "T495",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 133,
              "end_idx": 135,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T496",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 127,
              "end_idx": 131,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T497",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 127,
              "end_idx": 129,
              "entity_en": "T2"
            },
            {
              "entity_id": "T498",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 160,
              "end_idx": 164,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T499",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 160,
              "end_idx": 162,
              "entity_en": "T2"
            },
            {
              "entity_id": "T500",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 166,
              "end_idx": 168,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T501",
              "entity": "血脂",
              "entity_type": "Test_items",
              "start_idx": 172,
              "end_idx": 174,
              "entity_en": "Blood lipids"
            },
            {
              "entity_id": "T502",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 219,
              "end_idx": 222,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T503",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 224,
              "end_idx": 226,
              "entity_en": "blood sugar"
            },
            {
              "entity_id": "T504",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 249,
              "end_idx": 253,
              "entity_en": "T2DM"
            },
            {
              "entity_id": "T505",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 249,
              "end_idx": 251,
              "entity_en": "T2"
            },
            {
              "entity_id": "T506",
              "entity": "餐后血糖(PPG)",
              "entity_type": "Test_items",
              "start_idx": 257,
              "end_idx": 266,
              "entity_en": "Postprandial blood glucose (PPG)"
            },
            {
              "entity_id": "T507",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 266,
              "end_idx": 268,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T508",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 278,
              "end_idx": 281,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T509",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 287,
              "end_idx": 290,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T510",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 290,
              "end_idx": 292,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T511",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 302,
              "end_idx": 305,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T512",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 219,
              "end_idx": 222,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T513",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 320,
              "end_idx": 323,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T514",
              "entity": "增高",
              "entity_type": "Test_Value",
              "start_idx": 323,
              "end_idx": 325,
              "entity_en": "Increase"
            },
            {
              "entity_id": "T515",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 328,
              "end_idx": 333,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T516",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 333,
              "end_idx": 335,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T517",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 343,
              "end_idx": 346,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T518",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 346,
              "end_idx": 348,
              "entity_en": "Elevated"
            },
            {
              "entity_id": "T519",
              "entity": "糖尿病慢性并发症",
              "entity_type": "Disease",
              "start_idx": 349,
              "end_idx": 357,
              "entity_en": "Chronic complications of diabetes"
            },
            {
              "entity_id": "T520",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 371,
              "end_idx": 374,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T521",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 377,
              "end_idx": 382,
              "entity_en": "HbA1c"
            },
            {
              "entity_id": "T522",
              "entity": "糖尿病慢性发症",
              "entity_type": "Disease",
              "start_idx": 389,
              "end_idx": 396,
              "entity_en": "Chronic complications of diabetes"
            },
            {
              "entity_id": "T523",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 402,
              "end_idx": 405,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T524",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 412,
              "end_idx": 415,
              "entity_en": "PPG"
            },
            {
              "entity_id": "T525",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 421,
              "end_idx": 424,
              "entity_en": "FPG"
            },
            {
              "entity_id": "T526",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 442,
              "end_idx": 445,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T527",
              "entity": "糖尿病慢性并发症",
              "entity_type": "Disease",
              "start_idx": 68,
              "end_idx": 76,
              "entity_en": "Chronic complications of diabetes"
            },
            {
              "entity_id": "T528",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 520,
              "end_idx": 525,
              "entity_en": "Type 2 diabetes"
            },
            {
              "entity_id": "T529",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 520,
              "end_idx": 522,
              "entity_en": "Type 2"
            },
            {
              "entity_id": "T530",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 552,
              "end_idx": 555,
              "entity_en": "diabetes"
            },
            {
              "entity_id": "T531",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 459,
              "end_idx": 462,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T532",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 529,
              "end_idx": 532,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T533",
              "entity": "高血糖",
              "entity_type": "Disease",
              "start_idx": 484,
              "end_idx": 487,
              "entity_en": "High blood sugar"
            },
            {
              "entity_id": "T534",
              "entity": "血压",
              "entity_type": "Test",
              "start_idx": 169,
              "end_idx": 171,
              "entity_en": "blood pressure"
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R173",
              "head_entity_id": "T495",
              "tail_entity_id": "T496"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R174",
              "head_entity_id": "T497",
              "tail_entity_id": "T496"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R175",
              "head_entity_id": "T499",
              "tail_entity_id": "T498"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R176",
              "head_entity_id": "T500",
              "tail_entity_id": "T498"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R177",
              "head_entity_id": "T501",
              "tail_entity_id": "T498"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R178",
              "head_entity_id": "T534",
              "tail_entity_id": "T498"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R179",
              "head_entity_id": "T503",
              "tail_entity_id": "T512"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R180",
              "head_entity_id": "T505",
              "tail_entity_id": "T504"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R181",
              "head_entity_id": "T506",
              "tail_entity_id": "T504"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R182",
              "head_entity_id": "T509",
              "tail_entity_id": "T508"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R183",
              "head_entity_id": "T517",
              "tail_entity_id": "T519"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R184",
              "head_entity_id": "T520",
              "tail_entity_id": "T522"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R185",
              "head_entity_id": "T521",
              "tail_entity_id": "T522"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R186",
              "head_entity_id": "T524",
              "tail_entity_id": "T523"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R187",
              "head_entity_id": "T525",
              "tail_entity_id": "T523"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R188",
              "head_entity_id": "T529",
              "tail_entity_id": "T528"
            }
          ],
          "sentence_en": "The prevalence of diabetes in Chinese adults is as high as 9.7%, and the number of patients ranks first in the world. The key to diabetes prevention and treatment lies in active prevention, early diagnosis and early standardized intervention. The ultimate goal of diabetes management is to prevent and treat chronic complications of diabetes, including microvascular complications and atherosclerotic vascular disease (ASVD), so as to improve the quality of life of patients and prolong their life. Studies have shown that the blood sugar standard rate of outpatient T2DM patients in my country is only 32.6%; in terms of cardiovascular risk factor control, the blood sugar, blood pressure and blood lipid standards of T2DM patients in my country are 47.7%, 28.4% and 36.1% respectively, and only 5.6% of patients meet the standards for all three indicators. At present, the current status of blood sugar control and clinical rational drug use in diabetic patients in my country is not optimistic. Most Chinese T2DM patients are accompanied by elevated postprandial blood glucose (PPG). Among diabetic patients diagnosed by epidemiological screening, the proportion of patients with simple elevated PPG is as high as 50%, and about 70% of prediabetes are simple IGT. Increased PPG is one of the main causes of increased HbA1c, and increased PPG is correlated with the occurrence and development of chronic complications of diabetes. Therefore, controlling PPG is an important strategy to achieve HbA1c control and prevent chronic complications of diabetes. In the management of diabetes, the means of controlling PPG are significantly different from those of controlling FPG. In order to enable the majority of medical personnel engaged in diabetes prevention and treatment to have a more comprehensive understanding of the pathophysiological characteristics and clinical significance of postprandial hyperglycemia and to better apply control measures for postprandial hyperglycemia, some domestic experts have formulated the \"Expert Consensus on the Management of Postprandial Hyperglycemia in Chinese Patients with Type 2 Diabetes\" based on clinical evidence and clinical experience at home and abroad, in order to provide a reference for clinicians to better manage diabetes."
        }
      ],
      "paragraph_en": "The prevalence of diabetes in Chinese adults is as high as 9.7%, and the number of patients ranks first in the world. The key to diabetes prevention and treatment lies in active prevention, early diagnosis and early standardized intervention. The ultimate goal of diabetes management is to prevent and treat chronic complications of diabetes, including microvascular complications and atherosclerotic vascular disease (ASVD), so as to improve the quality of life of patients and prolong their life. Studies have shown that the blood sugar standard rate of outpatient T2DM patients in my country is only 32.6%; in terms of cardiovascular risk factor control, the blood sugar, blood pressure and blood lipid standards of T2DM patients in my country are 47.7%, 28.4% and 36.1% respectively, and only 5.6% of patients meet the standards for all three indicators. At present, the current status of blood sugar control and clinical rational drug use in diabetic patients in my country is not optimistic. Most Chinese T2DM patients are accompanied by elevated postprandial blood glucose (PPG). Among diabetic patients diagnosed by epidemiological screening, the proportion of patients with simple elevated PPG is as high as 50%, and about 70% of prediabetes are simple IGT. Increased PPG is one of the main causes of increased HbA1c, and increased PPG is correlated with the occurrence and development of chronic complications of diabetes. Therefore, controlling PPG is an important strategy to achieve HbA1c control and prevent chronic complications of diabetes. In the management of diabetes, the means of controlling PPG are significantly different from those of controlling FPG. In order to enable the majority of medical personnel engaged in diabetes prevention and treatment to have a more comprehensive understanding of the pathophysiological characteristics and clinical significance of postprandial hyperglycemia and to better apply control measures for postprandial hyperglycemia, some domestic experts have formulated the \"Expert Consensus on the Management of Postprandial Hyperglycemia in Chinese Patients with Type 2 Diabetes\" based on clinical evidence and clinical experience at home and abroad, in order to provide a reference for clinicians to better manage diabetes."
    }
  ]
}